var title_f36_17_37136="Carolis disease MRCP";
var content_f36_17_37136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Caroli's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance cholangiography in an infant with Caroli's disease. There is biliary ectasia throughout the liver and saccular dilatation of bile ducts in the left lobe (arrow). The kidneys show typical changes of autosomal recessive polycystic kidney disease with massive enlargement due to fusiform dilatation of the collecting ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frederick J Suchy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37136=[""].join("\n");
var outline_f36_17_37136=null;
var title_f36_17_37137="Patient information: Alcohol poisoning (The Basics)";
var content_f36_17_37137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/21/44371\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/23/4468\">",
"         Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Alcohol poisoning (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/alcohol-poisoning-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25801099\">",
"      <span class=\"h1\">",
"       What is alcohol poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Alcohol poisoning is what happens if someone drinks far too much in a short amount of time. This is different from being drunk or having a little too much to drink. Alcohol poisoning is life-threatening. A person with alcohol poisoning could stop breathing or choke on his or her own vomit.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25801106\">",
"      <span class=\"h1\">",
"       What are the symptoms of alcohol poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some of the symptoms are the same as those for a person who is &ldquo;just drunk.&rdquo; For instance, people who have alcohol poisoning can seem confused or have trouble standing up. But some of the other symptoms of alcohol poisoning are more serious. Alcohol poisoning can slow or stop a person&rsquo;s breathing. It can also cause seizures or an irregular heartbeat.",
"     </p>",
"     <p>",
"      <strong>",
"       Call 9-1-1",
"      </strong>",
"      if",
"      <strong>",
"      </strong>",
"      the person:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stops breathing or goes 10 seconds or more without breathing",
"       </li>",
"       <li>",
"        Is breathing very slowly (fewer than 8 breaths in 1 minute)",
"       </li>",
"       <li>",
"        Turns blue or very pale, and his or her skin feels cool to the touch &nbsp;",
"       </li>",
"       <li>",
"        Has a seizure",
"       </li>",
"       <li>",
"        Is passed out and cannot be woken up at all",
"       </li>",
"       <li>",
"        Cannot stop vomiting",
"       </li>",
"       <li>",
"        Looks very sick",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25801120\">",
"      <span class=\"h1\">",
"       What will the doctors at the hospital do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If someone goes to the emergency room with alcohol poisoning, the doctors there can make sure that the person:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keeps breathing. (If the person stops breathing, the doctors can put him or her on a breathing machine.)",
"       </li>",
"       <li>",
"        Gets fluids through a tube in a vein (IV) if needed. (This can be important if the person has been vomiting a lot.)",
"       </li>",
"       <li>",
"        Is healthy except for the alcohol. People who have been drinking sometimes have other problems that are tough to spot, because they cannot tell you what they are feeling. For instance, people who have been drinking often fall down or otherwise hurt themselves. Doctors can use x-rays and other tools to spot possible injuries or other health problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25801127\">",
"      <span class=\"h1\">",
"       Is there anything doctors can do to get the alcohol out of your system?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Alcohol is absorbed into the body very quickly. It does no good to empty the stomach. There is nothing that can soak up or cancel out the effects of the alcohol. The only thing that gets rid of alcohol in the body is time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25801134\">",
"      <span class=\"h1\">",
"       What can you do at home to help keep someone safe?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For people who have been drinking but do not seem to need emergency care, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keep checking their breathing and call 9-1-1 if their breathing slows too much or stops",
"       </li>",
"       <li>",
"        Lay them on their side, so that they do not choke on their own vomit if they throw up",
"       </li>",
"       <li>",
"        Check them for bumps, bruises, bleeding, or any sign of injury",
"       </li>",
"       <li>",
"        Make sure they stay warm (use blankets)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If someone you know drinks so much that you are afraid for his or her safety, that might be a sign of a drinking problem. When he or she recovers, it might be good to sit down and talk about what happened. Suggest speaking to a doctor, nurse, or mental health expert who can help diagnose and treat a drinking problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25801228\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=see_link\">",
"       Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/17/37137?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15842 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37137=[""].join("\n");
var outline_f36_17_37137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25801099\">",
"      What is alcohol poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25801106\">",
"      What are the symptoms of alcohol poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25801120\">",
"      What will the doctors at the hospital do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25801127\">",
"      Is there anything doctors can do to get the alcohol out of your system?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25801134\">",
"      What can you do at home to help keep someone safe?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25801228\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37138="Patient information: Intrauterine devices (IUD) (The Basics)";
var content_f36_17_37138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86384\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/2/7214\">",
"         Paragard IUD",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/5/19550\">",
"          Mirena IUD",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/28/12738\">",
"         Patient information: Emergency contraception (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/17/18707\">",
"         Patient information: Hormonal birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/22/1378\">",
"         Patient information: Long-acting methods of birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/51/23346\">",
"         Patient information: Sterilization for women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/16/4355\">",
"         Patient information: Long-term methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Intrauterine devices (IUD) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H100749003\">",
"      <span class=\"h1\">",
"       What is an intrauterine device?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An intrauterine device (IUD) is a type of birth control. It is a small, T-shaped device that a doctor or nurse puts through your vagina and cervix into your uterus. These devices are made of flexible plastic and have 2 plastic strings similar to fishing line that hang out of the cervix.",
"     </p>",
"     <p>",
"      An IUD is 1 of the safest, most effective methods for preventing pregnancy. It is a good choice for women who do not want to get pregnant for at least 1 year.",
"     </p>",
"     <p>",
"      Some women use IUDs for reasons other than birth control. For example, 1 type of IUD can be used to treat heavy, painful periods. The other type can be used to prevent pregnancy if it is put in within 5 days after a woman has sex without birth control. This is known as &ldquo;emergency contraception.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100749018\">",
"      <span class=\"h1\">",
"       What are the different types of IUDs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are 2 types of IUDs. One type releases copper; the other releases the hormone progestin.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Copper&ndash;releasing IUD &ndash; There is only 1 copper-releasing IUD. It is called Paragard (",
"        <a class=\"graphic graphic_picture graphicRef86255 \" href=\"mobipreview.htm?7/2/7214\">",
"         picture 1",
"        </a>",
"        ) and can stay in your uterus for up to 10 years to prevent pregnancy. Some women who use it get heavier or longer periods than they had before getting the IUD. Paragard also can be used for emergency contraception.",
"       </li>",
"       <li>",
"        Progestin-releasing IUD &ndash; There are 2 progestin-releasing IUDs, called Mirena and Skyla. Mirena (",
"        <a class=\"graphic graphic_picture graphicRef74378 \" href=\"mobipreview.htm?19/5/19550\">",
"         picture 2",
"        </a>",
"        ) can stay in your uterus for up to 5 years to prevent pregnancy. Skyla can stay in place for up to 3 years. Many women who use progestin-releasing IUDs have lighter, less painful periods than they had before getting the IUD. Some women stop getting a period at all. But this is not harmful and does not need to be treated. Regular periods return when the device is taken out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100749069\">",
"      <span class=\"h1\">",
"       What are the benefits of using an IUD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The benefits of using an IUD include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        IUDs are very effective. Fewer than 1 in 100 women who use these devices get pregnant during the first year of using them.",
"       </li>",
"       <li>",
"        You do not have to remember to do anything or take any birth control medicines on a regular basis.",
"       </li>",
"       <li>",
"        IUDs have few side effects.",
"       </li>",
"       <li>",
"        IUDs do not contain estrogen, a hormone that some women can&rsquo;t or don&rsquo;t want to take.",
"       </li>",
"       <li>",
"        If you decide you want to get pregnant, you can have the IUD taken out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100749086\">",
"      <span class=\"h1\">",
"       What are the downsides of an IUD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The downsides of an IUD include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Unlike condoms, an IUD does not protect you against infections you can catch during sex, called &ldquo;sexually transmitted diseases&rdquo; or &ldquo;STDs.&rdquo; But your partner can use a condom to protect against transmitting infection.",
"       </li>",
"       <li>",
"        There is a small chance the IUD will come out during your period. If this happens, you will need a new IUD.",
"        <br/>",
"        <br/>",
"        You should check your IUD once a month, after your period. To do this, use your finger to check that you can feel the string from the IUD coming out of your cervix. If you cannot feel the string, you should use another type of birth control (such as condoms) until you can see a doctor or nurse to check if your IUD is still in the right place.",
"       </li>",
"       <li>",
"        The initial cost is higher than the cost of other methods. But there is no cost for 3 to 10 years after the initial cost.",
"       </li>",
"       <li>",
"        Only a doctor or nurse can insert or remove an IUD.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should not get an IUD if you recently had an infection that spread to your uterus and other nearby organs, called a &ldquo;pelvic infection.&rdquo; STDs such as &ldquo;chlamydia&rdquo; and &ldquo;gonorrhea&rdquo; can cause pelvic infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100749103\">",
"      <span class=\"h1\">",
"       Which type of IUD is best for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your nurse or doctor can help you choose the right IUD for you. Paragard might be a good choice if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Want or need to avoid hormones. This includes women who have had blood clots in their legs.",
"       </li>",
"       <li>",
"        Want to avoid big changes in your period, such not having any periods or bleeding or spotting when you might not expect it.",
"       </li>",
"       <li>",
"        Want birth control for up to 10 years.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Mirena or Skyla might be a good choice if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have heavy, painful periods. Mirena and Skyla can make your periods lighter and less painful.",
"       </li>",
"       <li>",
"        Want birth control for up to 5 years.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100749120\">",
"      <span class=\"h1\">",
"       Does it hurt to have an IUD put in?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will likely feel some discomfort and slight cramping after the nurse or doctor puts the IUD into your uterus. Women who have not had a baby often feel more discomfort than women who have had a baby.",
"      <strong>",
"      </strong>",
"     </p>",
"     <p>",
"      After the IUD is in place, you should not be able to feel it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100749137\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have an IUD, see your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have bad pain in your lower belly",
"       </li>",
"       <li>",
"        Your period is late or very different from normal",
"       </li>",
"       <li>",
"        You cannot feel the string of the IUD or if the string seems shorter than usual",
"       </li>",
"       <li>",
"        You had sex with someone who has or might have an STD, or you think you have an STD",
"       </li>",
"       <li>",
"        You have an unexplained fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H100749152\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/28/12738?source=see_link\">",
"       Patient information: Emergency contraception (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=see_link\">",
"       Patient information: Hormonal birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/22/1378?source=see_link\">",
"       Patient information: Long-acting methods of birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/51/23346?source=see_link\">",
"       Patient information: Sterilization for women (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=see_link\">",
"       Patient information: Long-term methods of birth control (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/17/37138?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86384 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-3E1552308A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37138=[""].join("\n");
var outline_f36_17_37138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749003\">",
"      What is an intrauterine device?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749018\">",
"      What are the different types of IUDs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749069\">",
"      What are the benefits of using an IUD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749086\">",
"      What are the downsides of an IUD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749103\">",
"      Which type of IUD is best for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749120\">",
"      Does it hurt to have an IUD put in?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749137\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100749152\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/2/7214\">",
"      Paragard IUD",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/5/19550\">",
"       Mirena IUD",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/28/12738?source=related_link\">",
"      Patient information: Emergency contraception (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=related_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/22/1378?source=related_link\">",
"      Patient information: Long-acting methods of birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/51/23346?source=related_link\">",
"      Patient information: Sterilization for women (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37139="Nonoxynol 9: Drug information";
var content_f36_17_37139=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nonoxynol 9: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/12/39107?source=see_link\">",
"    see \"Nonoxynol 9: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Conceptrol&reg; [OTC];",
"     </li>",
"     <li>",
"      Delfen&reg; [OTC];",
"     </li>",
"     <li>",
"      Encare&reg; [OTC];",
"     </li>",
"     <li>",
"      Gynol II&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gynol II&reg; [OTC];",
"     </li>",
"     <li>",
"      Today&reg; [OTC];",
"     </li>",
"     <li>",
"      VCF&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Spermicide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Prior to use, refer to specific product labeling for complete instructions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of pregnancy:",
"     </b>",
"     Vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Conceptrol&reg;: Insert 1 applicatorful vaginally up to 1 hour prior to intercourse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Encare&reg;: Unwrap and insert 1 suppository vaginally at least 10 minutes prior to intercourse; effective for 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Today&reg;: Insert 1 sponge vaginally prior to intercourse; allow to remain in place for 6 hours after intercourse before removing; effective for use up to 24 continuous hours. Do not leave in place for &gt;30 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     VCF&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Film: Insert 1 film vaginally at least 15 minutes, but no more than 3 hours, prior to intercourse. Insert new film for each act of intercourse or if more than 3 hours have elapsed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Foam: Insert 1 applicatorful at least 15 minutes prior to intercourse; effective for up to 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delfen&reg;: 12.5% (18 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VCF&reg;: 12.5% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Film, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VCF&reg;: 28% (3s, 6s, 12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conceptrol&reg;: 4% (2.7 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Encare&reg;: 4% (2.7 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gynol II&reg;: 2% (108 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gynol II&reg; Extra Strength: 3% (81 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Today&reg;: 1 g (3s, 12s) [contains benzoic acid, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Encare&reg;: 100 mg (12s, 18s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F202254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Today&reg;: Prior to use, wet sponge with clean water and squeeze gently until sudsy in order to activate spermicide. Fold sponge in half with dimple side inside and string loop on bottom end, then insert into vagina. May be inserted up to 24 hours prior to intercourse. Sponge should not be reinserted if it accidentally falls out (insert new sponge).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     VCF&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Film: Remove film from pouch and fold in half; insert vaginally using finger.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Foam: Shake well prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Delfen&reg; may be confused with Delsym&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Genitourinary: Irritation, burning, or itching of mucous membranes (including vaginal/urethral)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F202256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nonoxynol 9 or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Today&reg;: Hypersensitivity to sulfites; use within 6 weeks after giving birth; history of toxic shock syndrome; use during menstrual period",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F202245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxic shock syndrome: Has been reported with barrier contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal irritation: May cause vaginal irritation (eg, burning, itching or rash); irritation may also be present without symptoms. Irritation may be associated with an increased risk of getting HIV from an infected partner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Today&reg;: Prior to use, patients should consult healthcare provider following recent miscarriage or abortion, or with vaginal or uterine conditions which may make the product ineffective (eg, vaginal septum, uterine prolapse).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Patients should consult with healthcare provider concerning the best form of birth control. For use in persons with only one partner and when neither partner is infected with HIV or has HIV risk factors; may be used with or without a diaphragm or condom.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Nonoxynol 9 does not protect against HIV infection or other sexually-transmitted diseases and use may increase the risk of getting HIV from an infected partner. Not for use in persons with HIV or those who have a sexual partner with HIV; another form of birth control should be used. Proper use of a latex condom will help reduce the risk of infection from HIV.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rectal use: Not for use as a microbicide or lubricant during anal intercourse. Rectal use may cause irritation, which may increase the risk of getting HIV from an infected partner.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14191327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of spermicides has not been associated with birth defects (FDA, 1986).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Film",
"     </b>",
"     (VCF Vaginal Contraceptive Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     28% (6): $4.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (VCF Vaginal Contraceptive Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5% (17 g): $7.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Conceptrol Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (2.7 g): $1.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Gynol II Extra Strength Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (85.5 g): $9.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Gynol II Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (75 g): $7.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      INST",
"     </b>",
"     (Conceptrol Inserts Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (10): $5.74",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Delfen (IL, IN, PT);",
"     </li>",
"     <li>",
"      Delfen II (ZA);",
"     </li>",
"     <li>",
"      Gynol-Plus (SE);",
"     </li>",
"     <li>",
"      Ortho-Creme (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F703201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Nonoxynol 9 is a surfactant which prevents pregnancy by damaging the cell membrane of sperm; some product formulations may also provide a physical barrier",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37139/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Data Do Not Support Association Between Spermicides, Birth Defects,\"",
"      <i>",
"       FDA Drug Bull",
"      </i>",
"      , 1986, 16(2):21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37139/abstract-text/3817349/pubmed\" id=\"3817349\" target=\"_blank\">",
"        3817349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10170 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37139=[""].join("\n");
var outline_f36_17_37139=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202259\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202268\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202261\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202262\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202252\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202242\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202254\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202253\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202274\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202266\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202256\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202245\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299771\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221949\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191327\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323525\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038707\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F703201\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10170\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10170|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/12/39107?source=related_link\">",
"      Nonoxynol 9: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37140="Rifaximin: Drug information";
var content_f36_17_37140=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rifaximin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/41/43667?source=see_link\">",
"    see \"Rifaximin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xifaxan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatic encephalopathy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reduction of overt hepatic encephalopathy recurrence: 550 mg 2 times/day.",
"     <b>",
"      Note:",
"     </b>",
"     Supporting clinical trial evaluated efficacy over 6-month treatment period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment of hepatic encephalopathy (unlabeled use): 400 mg every 8 hours for 5-10 days (Mas, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Travelers' diarrhea:",
"     </b>",
"     Oral: 200 mg 3 times/day for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Clostridium difficile",
"      </i>",
"     </b>",
"     <b>",
"      -associated diarrhea (unlabeled use):",
"     </b>",
"     Oral: 200-400 mg 2-3 times/day for 14 days (Johnson, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F218524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Travelers' diarrhea:",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10167004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not studied; no dosing recommendation available.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10167005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary, but use with caution in severe impairment (Child-Pugh class C) as systemic absorption does occur and pharmacokinetic parameters are highly variable.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xifaxan&reg;: 200 mg, 550 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F218498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of travelers' diarrhea caused by noninvasive strains of",
"     <i>",
"      E. coli",
"     </i>",
"     ; reduction in the risk of overt hepatic encephalopathy (HE) recurrence",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7764285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hepatic encephalopathy; alternative treatment for",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F803022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rifaximin may be confused with rifampin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency of adverse events generally higher following treatment for hepatic encephalopathy (HE). Percentages are presented for HE unless otherwise stated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (13%), fatigue (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Ascites (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&gt;2% to 5%), edema (&gt;2% to 5%), hypotension (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (travelers' diarrhea 10%), depression (7%), fever (6%), amnesia (&gt;2% to 5%), attention disturbance (&gt;2% to 5%), confusion (&gt;2% to 5%), hypoesthesia (&gt;2% to 5%), pain (&gt;2% to 5%), tremor (&gt;2% to 5%), vertigo (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatological: Pruritus (9%), rash (5%), cellulitis (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine and metabolism: Hyper-/hypoglycemia (&gt;2% to 5%), hyperkalemia (&gt;2% to 5%), hyponatremia (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (&gt;2% to 9%), abdominal tenderness (&gt;2% to 5%), anorexia (&gt;2% to 5%), dehydration (&gt;2% to 5%), esophageal varices (&gt;2% to 5%), weight gain (&gt;2% to 5%), xerostomia (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms (9%), arthralgia (6%), myalgia (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (7%), dyspnea (6%), epistaxis(&gt;2% to 5%), pneumonia (&gt;2% to 5%), rhinitis (&gt;2% to 5%), upper respiratory tract infection (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza-like illness (&gt;2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      All indications:",
"     </b>",
"     &lt;2% (Limited to important or life-threatening): Abnormal dreams, allergic dermatitis, anaphylaxis, angioneurotic edema, AST increased, choluria, CDAD, dry lips, dysuria, ear pain, exfoliative dermatitis, flushing, gingival disorder, hematuria, hot flashes, hypersensitivity reactions, lymphocytosis, migraine, monocytosis, motion sickness, nasal irritation, nasopharyngitis, neck pain, neutropenia, pharyngitis, pharyngolaryngeal pain, polyuria, proteinuria, sunburn, syncope, taste loss, tinnitus, urticaria, weakness, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rifaximin, other rifamycin antibiotics, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Appropriate use: Efficacy has not been established for the treatment of diarrhea due to pathogens other than",
"     <i>",
"      E. coli",
"     </i>",
"     , including",
"     <i>",
"      C. jejuni",
"     </i>",
"     ,",
"     <i>",
"      Shigella",
"     </i>",
"     , and",
"     <i>",
"      Salmonella",
"     </i>",
"     ; consider alternative therapy if symptoms persist or worsen after 24-48 hours of treatment; avoid use in diarrhea with fever or blood in the stool.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Efficacy for prevention of encephalopathy has not been established in patients with a Model for End-Stage Liver Disease (MELD) score &gt;25; use caution in patients with severe hepatic impairment (Child-Pugh class C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not for treatment of systemic infections; &lt;1% is absorbed orally.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies rifaximin as pregnancy category C. Due to the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the fetus is expected to be extremely low.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F218504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if rifaximin is excreted in human milk. Due to the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the nursing infant is expected to be extremely low. Use of rifaximin during breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xifaxan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $950.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     550 mg (60): $1482.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temperature, blood in stool, change in symptoms; monitor changes in mental status in hepatic encephalopathy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Colidimin (AT);",
"     </li>",
"     <li>",
"      Coloximina (AR);",
"     </li>",
"     <li>",
"      Faxinorm (DK);",
"     </li>",
"     <li>",
"      Flonorm (CO, MX);",
"     </li>",
"     <li>",
"      Ifaxim (CO);",
"     </li>",
"     <li>",
"      Lormyx (GR);",
"     </li>",
"     <li>",
"      Normix (BG, CZ, HN, IT, KP, TR);",
"     </li>",
"     <li>",
"      Qian Er Fen (CL);",
"     </li>",
"     <li>",
"      Rifadom (AR);",
"     </li>",
"     <li>",
"      Spiraxin (ES);",
"     </li>",
"     <li>",
"      Xifaxan (DE, PL);",
"     </li>",
"     <li>",
"      Xifaxanta (GB);",
"     </li>",
"     <li>",
"      Zaxine (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Travelers&rsquo; diarrhea: Low; Increased in prevention of hepatic encephalopathy with Child-Pugh class C having a greater exposure than A",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Healthy subjects: ~68%; Hepatic impairment: 62%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Hepatic encephalopathy prevention:  ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~97% as unchanged drug); urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bass NM, Mullen KD, Sanyal A, et al, &ldquo;Rifaximin Treatment in Hepatic Encephalopathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(12):1071-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37140/abstract-text/20335583/pubmed\" id=\"20335583\" target=\"_blank\">",
"        20335583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garey KW, Salazar M, Shah D, et al, &ldquo;Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(6):827-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37140/abstract-text/18430792/pubmed\" id=\"18430792\" target=\"_blank\">",
"        18430792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson S, Schriever C, Galang M, et al, &ldquo;Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy With Vancomycin and Rifaximin,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(6):846-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37140/abstract-text/17304459/pubmed\" id=\"17304459\" target=\"_blank\">",
"        17304459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maclayton DO and Eaton-Maxwell A, &ldquo;Rifaximin for Treatment of Hepatic Encephalopathy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2009, 43(1):77-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37140/abstract-text/19092143/pubmed\" id=\"19092143\" target=\"_blank\">",
"        19092143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mas A, Rod&eacute;s J, Sunyer L, et al, &ldquo;Comparison of Rifaximin and Lactitol in the Treatment of Acute Hepatic Encephalopathy: Results of a Randomized, Double-Blind, Double-Dummy, Controlled Clinical Trial,&rdquo;",
"      <i>",
"       J Hepatol",
"      </i>",
"      , 2003, 38(1):51-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37140/abstract-text/12480560/pubmed\" id=\"12480560\" target=\"_blank\">",
"        12480560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phongsamran PV, Kim JW, Cupo Abbott J, et al,  &ldquo;Pharmacotherapy for Hepatic Encephalopathy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2010, 70(9):1131-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37140/abstract-text/20518580/pubmed\" id=\"20518580\" target=\"_blank\">",
"        20518580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10202 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37140=[""].join("\n");
var outline_f36_17_37140=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218514\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218531\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218516\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218524\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218517\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10167004\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10167005\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218495\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218483\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218498\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218497\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764285\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803022\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218529\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218501\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218485\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218525\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218489\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218491\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218503\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218520\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218504\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218505\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218502\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218493\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539924\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218484\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218500\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10202\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10202|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/41/43667?source=related_link\">",
"      Rifaximin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37141="Meclizine: Drug information";
var content_f36_17_37141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meclizine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/33/13844?source=see_link\">",
"    see \"Meclizine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/62/18404?source=see_link\">",
"    see \"Meclizine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antivert&reg;;",
"     </li>",
"     <li>",
"      Bonine&reg; [OTC] [DSC];",
"     </li>",
"     <li>",
"      Dramamine&reg; Less Drowsy Formula [OTC];",
"     </li>",
"     <li>",
"      Medi-Meclizine [OTC];",
"     </li>",
"     <li>",
"      Trav-L-Tabs&reg; [OTC];",
"     </li>",
"     <li>",
"      VertiCalm&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Piperazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Motion sickness:",
"     </b>",
"     Oral: 25-50 mg 1 hour before travel, repeat dose every 24 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vertigo:",
"     </b>",
"     Oral: 25-100 mg daily in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F191767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/62/18404?source=see_link\">",
"      see \"Meclizine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16317851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as hydrochloride: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 12.5 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antivert&reg;: 12.5 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antivert&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dramamine&reg; Less Drowsy Formula: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medi-Meclizine: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trav-L-Tabs&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VertiCalm&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bonine&reg;: 25 mg [DSC] [scored; raspberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of symptoms of motion sickness; management of vertigo with diseases affecting the vestibular system",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Antivert&reg; may be confused with Anzemet&reg;, Axert&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to meclizine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloric/duodenal obstruction: Use with caution in patients with pyloric or duodenal obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria). Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lack of response: If vertigo does not respond in 1-2 weeks, it is advised to discontinue use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F191754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F191747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; however, an increased risk of fetal abnormalities has not been observed following maternal use of meclizine during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F191763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14386339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     It is not known if meclizine is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F191746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Antivert Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $92.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $146.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $277.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dramamine Less Drowsy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (8): $3.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Meclizine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $32.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $40.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Medi-Meclizine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (2): $0.20",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F191748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agyrax (BE, FR);",
"     </li>",
"     <li>",
"      Bonadoxina (CR, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Bonamina (CN);",
"     </li>",
"     <li>",
"      Bonamine (PH);",
"     </li>",
"     <li>",
"      Chiclida (CO);",
"     </li>",
"     <li>",
"      Clizine (TW);",
"     </li>",
"     <li>",
"      Dizitab (PH);",
"     </li>",
"     <li>",
"      Navicalm (PT);",
"     </li>",
"     <li>",
"      Postadoxine (PH);",
"     </li>",
"     <li>",
"      Postafen (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Postafene (BE);",
"     </li>",
"     <li>",
"      Sea-Legs (NZ);",
"     </li>",
"     <li>",
"      Suprimal (NL);",
"     </li>",
"     <li>",
"      Vertigol (PY);",
"     </li>",
"     <li>",
"      Vomiseda (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has central anticholinergic action by blocking chemoreceptor trigger zone; decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F191743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1 hour  (Wang, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~24 hours (Wang, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 7 L/kg (Wang, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to norchlorcyclizine (Wang, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5 hours (Wang, 2011a; Wang, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 3 hours (Wang, 2011a; Wang, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces as unchanged drug and metabolites (Wang, 2012)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37141/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oosterveld WJ, &ldquo;Vertigo: Current Concepts in Management,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1985, 30(3):275-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37141/abstract-text/3876202/pubmed\" id=\"3876202\" target=\"_blank\">",
"        3876202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park J, Logan R, and Pottage A, &ldquo;Drug-Induced Extrapyramidal Signs in Chronic Liver Disease - A Case Report,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1977, 11(1):117-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37141/abstract-text/872535/pubmed\" id=\"872535\" target=\"_blank\">",
"        872535",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang Z, Lee B, Pearce D, et al, \"Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2012, 52(9):1343-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37141/abstract-text/21903894/pubmed\" id=\"21903894\" target=\"_blank\">",
"        21903894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang Z, Qian S, Zhang Q, et al, \"Quantification of Meclizine in Human Plasma by High Performance Liquid Chromatography-Mass Spectrometry,\"",
"      <i>",
"       J Chromatogr B Analyt Technol Biomed Life Sci",
"      </i>",
"      , 2011, 879(1):95-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/17/37141/abstract-text/21163711/pubmed\" id=\"21163711\" target=\"_blank\">",
"        21163711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9597 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37141=[""].join("\n");
var outline_f36_17_37141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191757\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191772\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191760\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191767\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191761\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317851\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317852\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191739\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191726\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191741\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191779\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191770\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191744\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191730\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299654\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191754\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191736\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191747\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191763\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14386339\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191746\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191748\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191729\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191743\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/33/13844?source=related_link\">",
"      Meclizine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/62/18404?source=related_link\">",
"      Meclizine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37142="Ribavirin: Patient drug information";
var content_f36_17_37142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ribavirin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     see \"Ribavirin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/59/12216?source=see_link\">",
"     see \"Ribavirin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Copegus&reg;;",
"     </li>",
"     <li>",
"      Rebetol&reg;;",
"     </li>",
"     <li>",
"      Ribasphere&reg;;",
"     </li>",
"     <li>",
"      Ribasphere&reg; RibaPak&reg;;",
"     </li>",
"     <li>",
"      Virazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Virazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause a risky drop in your red blood cell count. Tell your doctor if you have heart or lung problems or if you are using a ventilator.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug alone to treat hepatitis C infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hepatitis C infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lung (respiratory) syncytial virus.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ribavirin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703327",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Autoimmune hepatitis, poor kidney function, sickle cell anemia, or thalassemia major.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of childbearing age, but are not using 2 kinds of birth control or if you are planning to get pregnant during your care or within 6 months after care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with a sex partner who is pregnant or plans on getting pregnant at any time while you are being treated or within 6 months after your care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hepatitis B or HIV disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697234",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an organ transplant, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam before starting care and then one every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may make liver disease worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust while using this drug and for 6 months after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 6 months after care ends. Use 2 kinds of birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug or within 6 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698676",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, if your woman partner gets pregnant while you are being treated or within 6 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug must be used with interferon alfa to treat hepatitis C.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take 2 pregnancy tests before starting this drug and monthly while using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695747",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take capsule or solution with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When capsules are used with peginterferon alfa-2b, take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will breathe in this drug from your mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules and solution in a refrigerator or at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store powder and tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11025 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37142=[""].join("\n");
var outline_f36_17_37142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026353\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026355\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026354\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026359\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026360\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026362\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026357\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026358\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026363\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026364\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=related_link\">",
"      Ribavirin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/59/12216?source=related_link\">",
"      Ribavirin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37143="Microduplication syndromes";
var content_f36_17_37143=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microduplication syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/17/37143/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/17/37143/contributors\">",
"     Carlos A Bacino, MD, FACMG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/17/37143/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/17/37143/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/17/37143/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/17/37143/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/17/37143/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10088450\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microduplications, or submicroscopic duplications, are chromosomal duplications that are too small to be detected by light microscopy using conventional cytogenetics methods. Specialized testing is needed to identify these duplications. Microduplications are typically one to three megabases (Mb) long and involve several contiguous genes. The exact size and location of a microduplication that causes a syndrome may vary, but a specific &ldquo;critical region&rdquo; is consistently involved. Most of the phenotypic effects of these microduplications are due to changes in a few critical dosage sensitive genes, or in some cases a single gene.",
"   </p>",
"   <p>",
"    The phenotype of microduplication syndromes is often less clear and less well-defined than for the corresponding microdeletion syndrome. In addition, some microduplication syndromes may be inherited from apparently normal parents raising important issues regarding incomplete penetrance and ascertainment bias in these newly described clinical entities.",
"   </p>",
"   <p>",
"    This topic reviews microduplication syndromes of chromosomes 1 to 22. Microdeletion syndromes, congenital abnormalities of the sex chromosomes, and other congenital chromosomal abnormalities, such as trisomies, are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34025?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10024?source=see_link\">",
"     \"Sex chromosome abnormalities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4404928\">",
"    <span class=\"h1\">",
"     OVERVIEW OF GENOMIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genomic disorders are diseases that result from the loss or gain of",
"    <span class=\"nowrap\">",
"     chromosomal/DNA",
"    </span>",
"    material. The most common and better delineated genomic disorders are divided in two main categories, those resulting from copy number losses (deletion syndromes) and copy number gains (duplication syndromes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28087?source=see_link\">",
"     \"Genomic disorders: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Copy number variations (CNVs) are submicroscopic genomic differences in the number of copies of one or more sections of DNA that result in DNA gains or losses (",
"    <a class=\"graphic graphic_figure graphicRef67644 \" href=\"mobipreview.htm?40/28/41412\">",
"     figure 1",
"    </a>",
"    ). Some CNVs are pathogenic and cause syndromic disorders with consistent phenotypic features, as are discussed here. Other CNVs are associated with disease susceptibility or resistance, and the same CNV can be associated with several diverse disorders. Still other CNVs are part of normal genetic variation and have no recognized disease association. Contiguous gene syndromes can occur when CNVs affect several adjacent genes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of genetic variation\", section on 'Copy number variations (CNVs)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=see_link&amp;anchor=H1031916#H1031916\">",
"     \"Basic principles of genetic disease\", section on 'Copy number variation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main mechanism that leads to disease in genomic disorders secondary to deletions and duplications is a change in the copy number of a dosage-sensitive gene or genes. Other disease mechanisms include interference with imprinted genes and with regulatory elements outside genes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28087?source=see_link&amp;anchor=H16722227#H16722227\">",
"     \"Genomic disorders: An overview\", section on 'Disease mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genomic disorders are typically detected by array comparative genomic hybridization (array CGH) (",
"    <a class=\"graphic graphic_figure graphicRef58888 \" href=\"mobipreview.htm?28/63/29687\">",
"     figure 2",
"    </a>",
"    ). Most laboratories confirm gains or losses detected on an array with an independent method such as fluorescent",
"    <em>",
"     in situ",
"    </em>",
"    hybridization (FISH), multiple ligation dependent probe amplification (MLPA), or quantitative PCR (Q-PCR). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link&amp;anchor=H15538652#H15538652\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Array comparative genomic hybridization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link&amp;anchor=H15538631#H15538631\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Fluorescence in situ hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10088412\">",
"    <span class=\"h1\">",
"     1q21.1 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent duplications in this region encompassing approximately 1.35 Mb are associated with macrocephaly and mild intellectual disabilities (speech delay, learning disabilities) (MIM #612475) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Psychiatric abnormalities and attention deficit hyperactivity disorder (ADHD) have also been reported.",
"    <em>",
"     HYDIN",
"    </em>",
"    is the gene implicated in this disorder. The presentation is variable, due to incomplete penetrance and variable expressivity. Thus, this microduplication is also seen in asymptomatic individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34025?source=see_link&amp;anchor=H86260767#H86260767\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '1q21.1 deletion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurodevelopmental evaluation is recommended. Patients may benefit from physical, occupational, and speech therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818213\">",
"    <span class=\"h1\">",
"     3q29 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This recurrent duplication has variable clinical findings and is the reciprocal rearrangement of the deletion.",
"    <em>",
"     PAK3",
"    </em>",
"    and",
"    <em>",
"     DPG2",
"    </em>",
"    are the critical gene candidates. Clinical findings include microcephaly; low-set, simple ears; downturned corners of the mouth; long, bushy eyebrows; long eyelashes; high nasal bridge; eye abnormalities (microphthalmia, cataracts, irides colobomas); cleft palate; and renal and cardiac anomalies (MIM #611936) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Mild to moderate intellectual disabilities are common, and patients may have speech delay. However, this duplication has been seen in apparently unaffected individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34025?source=see_link&amp;anchor=H86260980#H86260980\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '3q29 deletion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain imaging studies are recommended in the presence of microcephaly. Other screening studies include renal ultrasound, echocardiogram, and fundoscopic eye exam. Patients may benefit from physical, occupational, and speech therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818220\">",
"    <span class=\"h1\">",
"     5q35 MICRODUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;5q35 is the Sotos syndrome critical region that contains the Sotos syndrome gene,",
"    <em>",
"     NSD1",
"    </em>",
"    . The 5q35 microduplication syndrome is basically a reverse of the Sotos syndrome (overgrowth) phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Patients with duplications involving",
"    <em>",
"     NSD1",
"    </em>",
"    present with microcephaly, global developmental delay, short stature, growth retardation, and delayed bone age. Seizures have been reported in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34025?source=see_link&amp;anchor=H12329086#H12329086\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '5q35 deletion syndrome (Sotos syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommended screening studies include brain magnetic resonance imaging (MRI) and electroencephalogram (EEG). Growth should be monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818227\">",
"    <span class=\"h1\">",
"     7q11.23 DUPLICATION SYNDROME (WILLIAMS-BEUREN REGION DUPLICATION SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions in this region are associated with Williams syndrome (MIM #609757). The reciprocal duplication causes a different clinical phenotype characterized by hypotonia and global developmental delay, with speech delay that can range from moderate to severe. Many of these patients have been diagnosed with autism spectrum disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Dysmorphic features are mild and without a clear characteristic pattern. Brain abnormalities have been observed and seizures reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/10\">",
"     10",
"    </a>",
"    ]. The genes responsible for the phenotype are not yet known.",
"   </p>",
"   <p>",
"    Hearing evaluations are recommended to rule out other causes of speech delay. Other screening studies include speech evaluation, brain MRI, and EEG. Referral to speech therapy is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818234\">",
"    <span class=\"h1\">",
"     11p15 DUPLICATIONS IN BECKWITH-WIEDEMANN SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beckwith-Wiedemann syndrome (BWS, MIM #130650) can be caused by microduplication of the 11p15 region of paternal origin. The major clinical features of this syndrome are macrosomia, macroglossia, omphalocele, prominent eyes, ear creases, large kidneys, hyperplasia of pancreas, and hemihypertrophy. BWS is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818241\">",
"    <span class=\"h1\">",
"     15q11-13 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletion of this imprinted region causes",
"    <span class=\"nowrap\">",
"     Angelman/Prader-Willi",
"    </span>",
"    syndromes. Gains and duplications of this region are seen in some patients with autism (MIM #608636) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In most of the cases, the diagnosis of autism is associated with duplication of the maternally inherited allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These patients may also present with hypotonia, global developmental delay, ADHD, ataxia, and seizures. The Angelman syndrome gene,",
"    <em>",
"     UBE3A",
"    </em>",
"    , is the gene potentially responsible for the autism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H86261867#H86261867\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '15q11-13 maternal deletion syndrome (Angelman syndrome)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H8964746#H8964746\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '15q11-13 paternal deletion syndrome (Prader-Willi syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Formal developmental and autism evaluations are recommended. Assessment of seizures includes an EEG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=see_link\">",
"     \"Diagnosis of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14361?source=see_link\">",
"     \"Screening tools for autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=see_link\">",
"     \"Developmental and behavioral screening tests in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818248\">",
"    <span class=\"h1\">",
"     15q13.3 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 1.5 Mb microduplication is reciprocal to the 15q13.3 deletion and extends between breakpoints BP4 and BP5. Half of individuals ascertained with this duplication have a range of neuropsychiatric disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H8964753#H8964753\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '15q13.3 deletion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818255\">",
"    <span class=\"h1\">",
"     15q24 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is the reciprocal duplication of the 15q24 deletion (MIM #613406). The cases described share similar clinical features with the deletion syndrome, including mild intellectual disability, receding anterior hairline, broad medial eyebrows, hypertelorism, epicanthal folds, downslanting palpebral fissures, broad nasal base and high nasal bridge, full lower lip, joint laxity and in some cases contractures, and hypospadias and genital anomalies in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H8964767#H8964767\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '15q24 deletion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Formal developmental evaluation is recommended. Endocrine and urology evaluation is performed in males if needed. Patients may benefit from physical, occupational, and speech therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6228459\">",
"    <span class=\"h1\">",
"     16p13.3 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This duplication involves the Rubinstein-Taybi critical region and includes the",
"    <em>",
"     CREBBP",
"    </em>",
"    gene. Clinical features include normal growth, mild to moderate developmental delay, small and proximally implanted thumbs, long fingers, and mild arthrogryposis (multiple joint contractures) with camptodactyly (flexion deformities of the proximal interphalangeal joints). Dysmorphic features include deep-set eyes, narrow palpebral fissures, wide nasal bridge, long philtrum, and thin upper lip. This duplication is occasionally associated with heart defects (atrial septal defect [ASD], tetralogy of Fallot [TOF]), submucous cleft palate anomalies, and eye anomalies (strabismus, blepharophimosis, and ptosis). The penetrance of this duplication is variable, since it has been found in normal transmitting parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818262\">",
"    <span class=\"h1\">",
"     16p13.11 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings for this duplication that spans approximately 1.65 Mb include behavioral abnormalities, cognitive impairment, autism, congenital heart defects, and skeletal manifestations such as hypermobility, craniosynostosis, and polydactyly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818269\">",
"    <span class=\"h1\">",
"     16p11.2 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This recurrent rearrangement is the reciprocal event of the deletion in 16p11.2 that spans almost 600 kb. There is significant variability in the clinical manifestations, ranging from normal in the majority of cases to developmental delay and autistic spectrum disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. A number of other neurodevelopmental and behavioral disorders have been observed as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/27\">",
"     27",
"    </a>",
"    ]. Other clinical findings seen in patients with this duplication include thoracolumbar syringomyelia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H8964781#H8964781\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '16p11.2 deletion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Formal developmental and autism evaluations are recommended in affected patients. A spine MRI should be considered, since syringomyelia may be asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818276\">",
"    <span class=\"h1\">",
"     17p13.3 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;While deletions in the distal short arm of chromosome 17 cause Miller-Dieker lissencephaly syndrome, duplications in this region are associated with developmental delay, central nervous system (CNS) anomalies, and autism spectrum disorder (MIM #613215) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H2157762#H2157762\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '17p13.3 deletion syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two duplication types, Class I and Class II. The critical region for Class I spans 258 kb and includes six genes: exons 2 to 3 of",
"    <em>",
"     TUSC5",
"    </em>",
"    ,",
"    <em>",
"     YWHAE",
"    </em>",
"    ,",
"    <em>",
"     CRK",
"    </em>",
"    ,",
"    <em>",
"     MYO1C",
"    </em>",
"    ,",
"    <em>",
"     SKIP",
"    </em>",
"    , and exons 1 to 4 of",
"    <em>",
"     PITPNA",
"    </em>",
"    . It appears that",
"    <em>",
"     YWHAE",
"    </em>",
"    plays the main role in the CNS anomalies and autism phenotype, while",
"    <em>",
"     CRK",
"    </em>",
"    seems to be the gene responsible for growth restriction. The Class II duplication additionally includes",
"    <em>",
"     PAFAH1B1",
"    </em>",
"    that encodes",
"    <em>",
"     LIS1",
"    </em>",
"    (the lissencephaly gene responsible for lissencephaly type I).",
"   </p>",
"   <p>",
"    Clinical findings for Class I duplications include autistic features, behavioral problems, speech and motor delays, mild dysmorphic features (or none), hand and feet malformations (large hands, small distal phalanges), and overgrowth (a rare feature for a",
"    <span class=\"nowrap\">",
"     chromosomal/genomic",
"    </span>",
"    disorder). Class II duplications show a range from normal intellect to severe intellectual disability, hypotonia that can be severe, autism, ADHD, microcephaly, dysmorphic features, and severe growth restriction. There are no migration abnormalities in the brain even though",
"    <em>",
"     LIS1",
"    </em>",
"    is involved. However, corpus callosum dysgenesis and cerebellar volume loss have been reported.",
"    <em>",
"     LIS1",
"    </em>",
"    overexpression appears to lead to smaller brains based upon animal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/30\">",
"     30",
"    </a>",
"    ]. Other abnormalities for Class II duplications include craniosynostosis, intestinal malrotation, scoliosis, cardiovascular anomalies, and other skeletal anomalies.",
"   </p>",
"   <p>",
"    Formal developmental and autism evaluations are recommended. A brain MRI is also recommended in patients with Class II duplications. Patients may benefit from physical, occupational, and speech therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818283\">",
"    <span class=\"h1\">",
"     17p11.2 DUPLICATION SYNDROME (CHARCOT-MARIE-TOOTH TYPE 1A DISEASE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent 1.5 Mb duplications in 17p11.2 involving the",
"    <em>",
"     PMP22",
"    </em>",
"    (peripheral myelin protein 22) gene are responsible for Charcot-Marie-Tooth Type 1A (CMT1A) disease (MIM #118220).",
"    <em>",
"     PMP22",
"    </em>",
"    is a dosage sensitive gene that causes CMT1A when overexpressed and hereditary neuropathy with liability to pressure palsy (HNPP) when underexpressed. CMT1A is a demyelinating motor-sensory neuropathy clinically characterized by progressive distal neuromuscular weakness. These patients present with foot and ankle problems including pain, weakness, deformity, and paresthesias. Foot drop and bilateral pes cavus are common. The muscles are wasted distally and conserved proximally. CMT1A is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H86262795#H86262795\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '17p11.2 deletion syndrome (Hereditary neuropathy with liability to pressure palsy)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818290\">",
"    <span class=\"h1\">",
"     17p11.2 DUPLICATION SYNDROME (POTOCKI-LUPSKI SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This duplication, also known as Potocki-Lupski syndrome (PLS, MIM #610883), is reciprocal to the deletion on chromosome 17 that is responsible for Smith-Magenis syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The common duplication spans 3.7 Mb, but the critical region spans 1.3 Mb and includes the",
"    <em>",
"     RAI1",
"    </em>",
"    (retinoic acid receptor 1) gene, a dosage sensitive gene presumably involved in the neurobehavioral and autism phenotype seen in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H86262802#H86262802\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '17p11.2 deletion syndrome (Smith-Magenis syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical findings include infantile hypotonia, failure to thrive, intellectual disability, poor feeding, oropharyngeal dysplasia, and sleep apnea (obstructive and central sleep apnea with hypercarbia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/31,32,35\">",
"     31,32,35",
"    </a>",
"    ]. Speech development is significantly impaired, with delays, absent speech, delayed echolalia, and verbal apraxia. Autistic spectrum disorders are seen. Structural cardiovascular abnormalities (septal defects) are part of the spectrum and can be rather severe, including hypoplastic left heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/33,36\">",
"     33,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Formal developmental and autism evaluation are recommended. Other screening studies include a brain MRI, echocardiogram, swallowing evaluations, and sleep studies. Referral to physical, occupational, and speech therapies is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818297\">",
"    <span class=\"h1\">",
"     17q21.31 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This duplication involves the",
"    <em>",
"     MAPT",
"    </em>",
"    and",
"    <em>",
"     CRHR1",
"    </em>",
"    genes (MIM #613533) and is similarly mediated by the inversion repeats flanking the",
"    <em>",
"     MAPT",
"    </em>",
"    gene as seen in the deletion. In the few reports of this duplication, it is associated with variable clinical features that range from normal cognition to severe intellectual disability, hypotonia, and joint laxity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/37\">",
"     37",
"    </a>",
"    ]. Further reports are required to determine the clinical range of this duplication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H8964809#H8964809\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '17q21.31 deletion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818304\">",
"    <span class=\"h1\">",
"     22q11.2 DUPLICATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplications of the 22q11.2 region are reciprocal to the velocardiofacial syndrome",
"    <span class=\"nowrap\">",
"     (VCFS)/DiGeorge",
"    </span>",
"    syndrome (DGS) recurrent deletions. The size of the duplications ranges from 1.5 to 3 Mb, depending upon the low copy repeats (LCRs) involved in the rearrangement. The LCRs surrounding the region are known as LCR22A to LCR22D. The common duplication is 3 Mb long and encompasses LCR22A to LCR22B. The common duplication includes",
"    <em>",
"     TBX1",
"    </em>",
"    , the putative gene for the congenital heart defects seen in this condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H86263283#H86263283\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '22q11.2 deletion syndromes (DiGeorge syndrome/Velocardiofacial syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features share some similarities with",
"    <span class=\"nowrap\">",
"     VCFS/DGS,",
"    </span>",
"    including mild to severe intellectual disability (deficits of memory performance, perceptual organization, and verbal comprehension; ADHD; and speech impairment), growth restriction, velopharyngeal incompetence, heart defects, and palatal abnormalities. Heart defects reported share similarities with the deletion, and include defects affecting the outflow ventricular tracts and other conotruncal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Other clinical findings reported include visual and hearing impairment, seizures, microcephaly, ptosis, and urogenital abnormalities. Many of these duplications are inherited, some of them from unaffected parents, therefore caution should be applied in interpreting genetic testing results and counseling families appropriately given the inter- and intrafamilial variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening studies include formal developmental evaluation, echocardiogram, and swallowing evaluations. Patients may benefit from physical, occupational, and speech therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12818311\">",
"    <span class=\"h1\">",
"     22q13 DUPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplications of the 22q13 region have been reported in a few children with infantile hypotonia, mild to moderate developmental delay, microcephaly, autism spectrum disorder, growth deficiency, and mild dysmorphic facial features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/43\">",
"     43",
"    </a>",
"    ]. This region includes several genes associated with mitochondrial function, and one patient with 22q13 duplication has been reported with mitochondrial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37143/abstract/44\">",
"     44",
"    </a>",
"    ]. The critical region includes the",
"    <em>",
"     SHANK3",
"    </em>",
"    gene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H8964823#H8964823\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '22q13.3 deletion syndrome (Phelan-McDermid syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10089610\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genomic disorders are diseases that result from the loss or gain of",
"      <span class=\"nowrap\">",
"       chromosomal/DNA",
"      </span>",
"      material. The most common and better delineated genomic disorders are divided in two main categories, those resulting from copy number losses (deletion syndromes) and copy number gains (duplication syndromes). (See",
"      <a class=\"local\" href=\"#H4404928\">",
"       'Overview of genomic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microduplications, or submicroscopic duplications, are chromosomal duplications that are too small to be detected by light microscopy using conventional cytogenetics methods. (See",
"      <a class=\"local\" href=\"#H10088450\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deletions in the 7q11.23 region are associated with Williams syndrome (MIM #609757). The reciprocal duplication causes a different clinical phenotype characterized by hypotonia and global developmental delay, with speech delay that can range from moderate to severe. (See",
"      <a class=\"local\" href=\"#H12818227\">",
"       '7q11.23 duplication syndrome (Williams-Beuren region duplication syndrome)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gains and duplications of the 15q11-13 region are seen in some patients with autism (MIM #608636). These patients may also present with hypotonia, global developmental delay, attention deficit hyperactivity disorder (ADHD), ataxia, and seizures. (See",
"      <a class=\"local\" href=\"#H12818241\">",
"       '15q11-13 duplication syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent 1.5 Mb duplications in 17p11.2 involving the",
"      <em>",
"       PMP22",
"      </em>",
"      (peripheral myelin protein 22) gene are responsible for Charcot-Marie-Tooth Type 1A (CMT1A) disease (MIM #118220). CMT1A is a demyelinating motor-sensory neuropathy clinically characterized by progressive distal neuromuscular weakness. (See",
"      <a class=\"local\" href=\"#H12818283\">",
"       '17p11.2 duplication syndrome (Charcot-Marie-Tooth type 1A disease)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Duplications of the 22q11.2 region are reciprocal to the velocardiofacial syndrome",
"      <span class=\"nowrap\">",
"       (VCFS)/DiGeorge",
"      </span>",
"      syndrome (DGS) recurrent deletions. The clinical features share some similarities with",
"      <span class=\"nowrap\">",
"       VCFS/DGS,",
"      </span>",
"      including mild to severe intellectual disability (deficits of memory performance, perceptual organization, and verbal comprehension; ADHD; and speech impairment), growth restriction, velopharyngeal incompetence, heart defects, and palatal abnormalities. Other clinical findings reported include visual and hearing impairment, seizures, microcephaly, ptosis, and urogenital abnormalities. (See",
"      <a class=\"local\" href=\"#H12818304\">",
"       '22q11.2 duplication syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/1\">",
"      Brunetti-Pierri N, Berg JS, Scaglia F, et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet 2008; 40:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/2\">",
"      Mefford HC, Sharp AJ, Baker C, et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 2008; 359:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/3\">",
"      Ballif BC, Theisen A, Coppinger J, et al. Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication. Mol Cytogenet 2008; 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/4\">",
"      Goobie S, Knijnenburg J, Fitzpatrick D, et al. Molecular and clinical characterization of de novo and familial cases with microduplication 3q29: guidelines for copy number variation case reporting. Cytogenet Genome Res 2008; 123:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/5\">",
"      Lisi EC, Hamosh A, Doheny KF, et al. 3q29 interstitial microduplication: a new syndrome in a three-generation family. Am J Med Genet A 2008; 146A:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/6\">",
"      Franco LM, de Ravel T, Graham BH, et al. A syndrome of short stature, microcephaly and speech delay is associated with duplications reciprocal to the common Sotos syndrome deletion. Eur J Hum Genet 2010; 18:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/7\">",
"      Zhang H, Lu X, Beasley J, et al. Reversed clinical phenotype due to a microduplication of Sotos syndrome region detected by array CGH: microcephaly, developmental delay and delayed bone age. Am J Med Genet A 2011; 155A:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/8\">",
"      Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011; 70:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/9\">",
"      Berg JS, Brunetti-Pierri N, Peters SU, et al. Speech delay and autism spectrum behaviors are frequently associated with duplication of the 7q11.23 Williams-Beuren syndrome region. Genet Med 2007; 9:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/10\">",
"      Torniero C, Dalla Bernardina B, Novara F, et al. Dysmorphic features, simplified gyral pattern and 7q11.23 duplication reciprocal to the Williams-Beuren deletion. Eur J Hum Genet 2008; 16:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/11\">",
"      Baker P, Piven J, Schwartz S, Patil S. Brief report: duplication of chromosome 15q11-13 in two individuals with autistic disorder. J Autism Dev Disord 1994; 24:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/12\">",
"      Bolton PF, Dennis NR, Browne CE, et al. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. Am J Med Genet 2001; 105:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/13\">",
"      Piard J, Philippe C, Marvier M, et al. Clinical and molecular characterization of a large family with an interstitial 15q11q13 duplication. Am J Med Genet A 2010; 152A:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/14\">",
"      Bundey S, Hardy C, Vickers S, et al. Duplication of the 15q11-13 region in a patient with autism, epilepsy and ataxia. Dev Med Child Neurol 1994; 36:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/15\">",
"      Flejter WL, Bennett-Baker PE, Ghaziuddin M, et al. Cytogenetic and molecular analysis of inv dup(15) chromosomes observed in two patients with autistic disorder and mental retardation. Am J Med Genet 1996; 61:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/16\">",
"      van Bon BW, Mefford HC, Menten B, et al. Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet 2009; 46:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/17\">",
"      El-Hattab AW, Smolarek TA, Walker ME, et al. Redefined genomic architecture in 15q24 directed by patient deletion/duplication breakpoint mapping. Hum Genet 2009; 126:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/18\">",
"      Kiholm Lund AB, Hove HD, Kirchhoff M. A 15q24 microduplication, reciprocal to the recently described 15q24 microdeletion, in a boy sharing clinical features with 15q24 microdeletion syndrome patients. Eur J Med Genet 2008; 51:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/19\">",
"      Marangi G, Leuzzi V, Orteschi D, et al. Duplication of the Rubinstein-Taybi region on 16p13.3 is associated with a distinctive phenotype. Am J Med Genet A 2008; 146A:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/20\">",
"      Thienpont B, B&eacute;na F, Breckpot J, et al. Duplications of the critical Rubinstein-Taybi deletion region on chromosome 16p13.3 cause a novel recognisable syndrome. J Med Genet 2010; 47:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/21\">",
"      Nagamani SC, Erez A, Bader P, et al. Phenotypic manifestations of copy number variation in chromosome 16p13.11. Eur J Hum Genet 2011; 19:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/22\">",
"      Ramalingam A, Zhou XG, Fiedler SD, et al. 16p13.11 duplication is a risk factor for a wide spectrum of neuropsychiatric disorders. J Hum Genet 2011; 56:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/23\">",
"      Fernandez BA, Roberts W, Chung B, et al. Phenotypic spectrum associated with de novo and inherited deletions and duplications at 16p11.2 in individuals ascertained for diagnosis of autism spectrum disorder. J Med Genet 2010; 47:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/24\">",
"      Weiss LA, Shen Y, Korn JM, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/25\">",
"      Kumar RA, Marshall CR, Badner JA, et al. Association and mutation analyses of 16p11.2 autism candidate genes. PLoS One 2009; 4:e4582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/26\">",
"      Kumar RA, KaraMohamed S, Sudi J, et al. Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet 2008; 17:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/27\">",
"      McCarthy SE, Makarov V, Kirov G, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009; 41:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/28\">",
"      Schaaf CP, Goin-Kochel RP, Nowell KP, et al. Expanding the clinical spectrum of the 16p11.2 chromosomal rearrangements: three patients with syringomyelia. Eur J Hum Genet 2011; 19:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/29\">",
"      Bruno DL, Anderlid BM, Lindstrand A, et al. Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes. J Med Genet 2010; 47:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/30\">",
"      Bi W, Sapir T, Shchelochkov OA, et al. Increased LIS1 expression affects human and mouse brain development. Nat Genet 2009; 41:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/31\">",
"      Potocki L, Bi W, Treadwell-Deering D, et al. Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am J Hum Genet 2007; 80:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/32\">",
"      Potocki L, Chen KS, Park SS, et al. Molecular mechanism for duplication 17p11.2- the homologous recombination reciprocal of the Smith-Magenis microdeletion. Nat Genet 2000; 24:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/33\">",
"      Yusupov R, Roberts AE, Lacro RV, et al. Potocki-Lupski syndrome: an inherited dup(17)(p11.2p11.2) with hypoplastic left heart. Am J Med Genet A 2011; 155A:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/34\">",
"      Carmona-Mora P, Walz K. Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior. Curr Genomics 2010; 11:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/35\">",
"      Soler-Alfonso C, Motil KJ, Turk CL, et al. Potocki-Lupski syndrome: a microduplication syndrome associated with oropharyngeal dysphagia and failure to thrive. J Pediatr 2011; 158:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/36\">",
"      Sanchez-Valle A, Pierpont ME, Potocki L. The severe end of the spectrum: Hypoplastic left heart in Potocki-Lupski syndrome. Am J Med Genet A 2011; 155A:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/37\">",
"      Kirchhoff M, Bisgaard AM, Duno M, et al. A 17q21.31 microduplication, reciprocal to the newly described 17q21.31 microdeletion, in a girl with severe psychomotor developmental delay and dysmorphic craniofacial features. Eur J Med Genet 2007; 50:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/38\">",
"      Ensenauer RE, Adeyinka A, Flynn HC, et al. Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. Am J Hum Genet 2003; 73:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/39\">",
"      Ou Z, Berg JS, Yonath H, et al. Microduplications of 22q11.2 are frequently inherited and are associated with variable phenotypes. Genet Med 2008; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/40\">",
"      Yobb TM, Somerville MJ, Willatt L, et al. Microduplication and triplication of 22q11.2: a highly variable syndrome. Am J Hum Genet 2005; 76:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/41\">",
"      Courtens W, Schramme I, Laridon A. Microduplication 22q11.2: a benign polymorphism or a syndrome with a very large clinical variability and reduced penetrance?--Report of two families. Am J Med Genet A 2008; 146A:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/42\">",
"      Wentzel C, Fernstr&ouml;m M, Ohrner Y, et al. Clinical variability of the 22q11.2 duplication syndrome. Eur J Med Genet 2008; 51:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/43\">",
"      Okamoto N, Kubota T, Nakamura Y, et al. 22q13 Microduplication in two patients with common clinical manifestations: a recognizable syndrome? Am J Med Genet A 2007; 143A:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37143/abstract/44\">",
"      Frye RE. Mitochondrial disease in 22q13 duplication syndrome. J Child Neurol 2012; 27:942.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13557 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37143=[""].join("\n");
var outline_f36_17_37143=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10089610\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10088450\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4404928\">",
"      OVERVIEW OF GENOMIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10088412\">",
"      1q21.1 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818213\">",
"      3q29 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818220\">",
"      5q35 MICRODUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818227\">",
"      7q11.23 DUPLICATION SYNDROME (WILLIAMS-BEUREN REGION DUPLICATION SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818234\">",
"      11p15 DUPLICATIONS IN BECKWITH-WIEDEMANN SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818241\">",
"      15q11-13 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818248\">",
"      15q13.3 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818255\">",
"      15q24 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6228459\">",
"      16p13.3 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818262\">",
"      16p13.11 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818269\">",
"      16p11.2 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818276\">",
"      17p13.3 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818283\">",
"      17p11.2 DUPLICATION SYNDROME (CHARCOT-MARIE-TOOTH TYPE 1A DISEASE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818290\">",
"      17p11.2 DUPLICATION SYNDROME (POTOCKI-LUPSKI SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818297\">",
"      17q21.31 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818304\">",
"      22q11.2 DUPLICATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12818311\">",
"      22q13 DUPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10089610\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13557|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/28/41412\" title=\"figure 1\">",
"      Nonhomologous recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/63/29687\" title=\"figure 2\">",
"      Schematic CGH for microarray setup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28087?source=related_link\">",
"      Genomic disorders: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34025?source=related_link\">",
"      Microdeletion syndromes (chromosomes 1 to 11)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14361?source=related_link\">",
"      Screening tools for autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10024?source=related_link\">",
"      Sex chromosome abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37144="AGEP histo 2";
var content_f36_17_37144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Histopathologic features of acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This higher power field shows epidermal spongiosis with exocytosis of neutrophils and eosinophils. Small microvesicles/microabscesses are developing. In other fields (not shown), there is subcorneal pustule formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Greg Hosler, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37144=[""].join("\n");
var outline_f36_17_37144=null;
var title_f36_17_37145="Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy";
var content_f36_17_37145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/17/37145/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/17/37145/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/17/37145/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/17/37145/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/17/37145/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/17/37145/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/17/37145/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/17/37145/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Hodgkin lymphoma (formerly called Hodgkin's disease) will attain a remission after induction chemotherapy with or without radiation therapy. However, relapse rates range from 10 to 20 percent in favorable prognosis stage I-II disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/1\">",
"     1",
"    </a>",
"    ] to 30 to 40 percent in patients with more advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In addition, approximately 10 to 15 percent of patients experience progression of disease after a partial initial response.",
"   </p>",
"   <p>",
"    Salvage therapy with second (or third) line regimens can achieve responses in approximately 50 percent of these patients, although long-term disease-free survival following the treatment of relapse with chemotherapy alone is unusual. Selected patients with poor prognosis after first relapse, patients with a second relapse, and patients with progressive disease are candidates for high dose chemotherapy followed by hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this discussion, the following definitions will apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse (or recurrence) is the reappearance of disease in sites of prior disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in new sites after initial therapy and attainment of complete response (CR).",
"     </li>",
"     <li>",
"      Progression refers to increasing evidence of disease after achieving a stable partial remission.",
"     </li>",
"     <li>",
"      Refractory disease is a failure to achieve a complete or partial response. The refractoriness can be primary (failure to respond to initial therapy) or secondary (initial response but failure to respond after disease relapse).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The vast majority of relapses from complete remission or induction failure will be in the setting of combination chemotherapy with or without complementary radiation therapy. Approximately 30 to 40 percent of patients with advanced Hodgkin lymphoma (unfavorable, stages IIB-IV) will have relapsed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refractory disease after initial chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Of these, 32 to 38 percent will have failed induction therapy (resistant disease), 27 to 38 percent will have relapsed less than 12 months after having obtained a CR, and 24 to 40 percent will have relapsed more than one year after attaining a CR. In almost all series, the latter is the most favorable for successful salvage.",
"   </p>",
"   <p>",
"    The treatment of relapse after initial treatment with chemotherapy will be reviewed here. Treatment primarily consists of combination chemotherapy with or without radiotherapy; radiotherapy alone is usually not used. The role of high dose chemotherapy and hematopoietic stem cell transplantation, the prognostic factors for and the presentation and diagnosis of relapse after chemotherapy, and issues related to relapse after initial treatment with radiotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7784?source=see_link\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9396345\">",
"    <span class=\"h1\">",
"     CONFIRMING RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of relapses following an apparent complete remission will occur within three years of therapy. Approximately 42 percent of relapses will occur within the first 12 months; an additional 24 percent will occur at one to three years. Late relapses (ie, &gt;3 years following treatment) occur at the rate of a few percent per year, extending up to 12 years post-treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7784?source=see_link\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9396352\">",
"    <span class=\"h2\">",
"     Detection of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up procedures for the detection of relapse after initial treatment vary somewhat from institution to institution. They generally assume a schedule of examination every three to four months for the first two years followed by every six months thereafter, and annually after four to five years. Most recurrences present with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mass lesion detected on physical examination. When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The screening value of procedures other than history and physical examination and possibly chest X-ray is not clear. Retrospective reviews of follow-up procedures in patients treated for Hodgkin lymphoma with chemotherapy alone reveal that the majority of relapses are detected as a result of investigation of symptoms rather than routine examination, blood tests, or radiographs. As an example, one study reviewed the records of 210 patients who were followed after having achieved a complete or partial remission of Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/13\">",
"     13",
"    </a>",
"    ]. Thirty-seven relapses were detected in a total of 2512 clinic visits. Thirty relapses (81 percent) were diagnosed in symptomatic patients; one-half of these symptomatic relapses resulted in an earlier appointment being scheduled. In only four cases was relapse detected as a result of routine physical examination in an asymptomatic patient.",
"   </p>",
"   <p>",
"    One cost effectiveness analysis has suggested that routine CT not be used in the surveillance of asymptomatic patients in CR after treatment of Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9396359\">",
"    <span class=\"h2\">",
"     Sites of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sites of relapse are often in previous areas of involvement, unless complementary radiation therapy has been administered. In that instance, relapse will more likely occur in previously uninvolved nodal regions or extranodal sites such as the liver or lungs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 75 percent of relapses after primary treatment with MOPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) were in nodal sites and 92 percent were in sites of prior disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/15\">",
"       15",
"      </a>",
"      ]. The central axial nodal areas and the left supraclavicular region were the most common nodal sites of relapse. New nodal sites tended to be adjacent to prior sites of disease.",
"     </li>",
"     <li>",
"      In another series, 427 patients were treated with chemotherapy (MOPP or ABVD [",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ]) as the main treatment modality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/16\">",
"       16",
"      </a>",
"      ]. Radiation therapy (30 Gy) was added to bulky and contiguous uninvolved nodal sites in 38 percent. Among 373 complete responders, 85 (23 percent) relapsed; 71 percent of the relapses were in nodal sites, and the remainders were extranodal with or without nodal sites. Only 13 percent recurred in previously irradiated lymph nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9396373\">",
"    <span class=\"h2\">",
"     Residual radiographic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to categorize any residual radiographic abnormalities after initial treatment to distinguish complete remission from partial remission and prevent unnecessary toxic therapy. Diagnosis of recurrence is generally made with biopsy of a mass and clinical staging is performed for prognosis. Clinical experience indicates that residual abnormalities on computed tomographic (CT) scans that persist after treatment of large lymph node masses with radiation therapy (with or without chemotherapy), especially in the mediastinum, may represent a complete remission (complete remission unconfirmed, CRu) with only residual fibrosis and necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/17\">",
"     17",
"    </a>",
"    ], or may represent residual disease activity. Currently, PET scanning is the diagnostic modality of choice for evaluating such residual CT abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link&amp;anchor=H9#H9\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PET scans have added considerably to the assessment of remission or persistent disease following salvage therapy prior to high-dose chemotherapy and hematopoietic cell transplantation (HCT). Residual fibrotic, necrotic masses on CT scan suggest incomplete response, however, case series have demonstrated a relapse rate of only 20 percent if the PET scan is negative prior to HCT compared with a relapse rate of 76 percent if the PET scan is positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The status of post-treatment PET scans has been reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9396380\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical judgment often determines whether or not relapse should be documented by biopsy, but it is sound practice to obtain a tissue diagnosis in most patients. This is especially true in the setting of late relapse, since there is a significant risk for second cancers (non-Hodgkin lymphoma or solid tumors) in these patients. In an instructive report, three young patients with Hodgkin lymphoma and gallium-avid nodal enlargement at 2.5 to 3 years post-treatment were found to have benign sarcoid-like lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible exception to this general rule is early recurrence in the setting of incomplete remission, especially with persistence of constitutional symptoms or measurable radiographic abnormalities; such patients may not need a repeat biopsy. However, a biopsy may be warranted in this setting to confirm the initial diagnosis of Hodgkin lymphoma if the disease has been unusually resistant to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9396387\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all cases, clinical restaging is recommended at the time of relapse, especially if there appears to be an isolated relapse. Restaging is performed both for prognosis and for determining treatment. Most patients will receive systemic or combined modality therapy for relapse; however, the extent of relapse determines the number of cycles of chemotherapy and the radiation field treated.",
"   </p>",
"   <p>",
"    A number of restaging schemes have been proposed for relapsed Hodgkin lymphoma. The most straightforward simply employs the Ann Arbor staging system criteria to describe the extent of disease identified at the time of relapse and substitutes the letters RS (relapse stage) for CS (clinical stage) or PS (pathological stage). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link&amp;anchor=H10#H10\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'PET/CT scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Hodgkin lymphoma relapsing after prior treatment with chemotherapy are generally treated with either conventional chemotherapy combined with radiation therapy or high dose chemotherapy and transplantation given with or without radiation therapy. The choice of therapy is usually based upon prognostic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salvage chemotherapy to obtain a second complete response followed by high dose chemotherapy and autologous hematopoietic cell transplantation with or without radiation therapy should be considered as the treatment of choice for the following subsets of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"       \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early relapse (less than 12 months after treatment) or induction failure.",
"     </li>",
"     <li>",
"      Second relapse after conventional treatment for first relapse.",
"     </li>",
"     <li>",
"      Generalized systemic relapse even beyond 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a relapse occurring more than 12 months after initial treatment (late relapse) and in whom the relapse is confined to a limited number of sites without constitutional symptoms have a better prognosis than the patients described above and this subgroup may be treated with conventional salvage chemotherapy, often combined with radiation therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach to patients with late relapse is primarily supported by studies that have demonstrated favorable outcomes in patients with a limited extent of disease and a complete response (CR) duration prior to relapse of greater than 12 months. As an example, patients in one study whose initial CR lasted more than 12 months had superior survival rates at eight years (54 versus 28 percent) when compared with those who had a shorter CR duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/7\">",
"     7",
"    </a>",
"    ]. Only 8 percent of patients who never achieved a CR (ie, induction failures) were alive at eight years.",
"   </p>",
"   <p>",
"    Several other studies have described the risk of death after relapse as a function of the number of adverse factors present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Cancer Control Agency of British Columbia analyzed a series of 80 patients who relapsed after primary systemic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/24\">",
"       24",
"      </a>",
"      ]. Three negative prognostic factors for outcome of second-line therapy were identified: duration of first remission less than 12 months; initial stage IV disease; and B symptoms at relapse. The second failure-free survival rate at a median follow-up of 75 months was 17 percent in patients with any one of these factors compared with 82 percent in patients with no unfavorable factors.",
"     </li>",
"     <li>",
"      Another report evaluated 187 patients who relapsed following primary radiation therapy or chemotherapy for a variety of initial factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/25\">",
"       25",
"      </a>",
"      ]. Multivariate analysis indicated that freedom from second failure was adversely affected by first remission duration less than 12 months and stage III-IV at relapse. The five-year relapse-free survival (RFS) and overall survival (OS) were calculated according to the number of these negative factors. Patients with 0, 1 and 2 factors had a RFS of 62, 47, and 32 percent, respectively, and an OS of 87, 59, and 44 percent, respectively.",
"     </li>",
"     <li>",
"      A report from the German Hodgkin's Lymphoma Study Group identified three adverse risk factors in patients relapsing following primary radiation therapy or chemotherapy (time to recurrence &le;12 months, stage III or IV disease at relapse, and hemoglobin &lt;10.5 or &lt;12.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in females and males, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/8\">",
"       8",
"      </a>",
"      ]. These three risk factors were incorporated into a recurring Hodgkin lymphoma prognostic score; actuarial four-year overall survival for patients relapsing after chemotherapy was 83, 66, 36, and 27 percent for those with zero, one, two, or three unfavorable factors, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further discussion of prognostic factors for relapse is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=see_link&amp;anchor=H3#H3\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACHIEVING A SECOND COMPLETE RESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy for most patients with relapsed Hodgkin lymphoma is to attain a second complete response (as defined by",
"    <span class=\"nowrap\">",
"     CT/PET)",
"    </span>",
"    or an unconfirmed complete response (as defined by CT) prior to high-dose therapy with autologous hematopoietic cell transplantation. A subset of patients with relapse occurring more than 12 months after initial treatment may be candidates for conventional salvage chemotherapy with or without radiation therapy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Late first relapse'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of achieving a second complete response prior to transplantation is supported by emerging experience with PET scans obtained at the end of salvage chemotherapy but prior to high-dose therapy with autologous transplant. In this setting, a negative scan has a markedly positive predictive value with 93 percent progression-free survival at two years in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/26\">",
"     26",
"    </a>",
"    ]. This prognostic value has been confirmed in other trials. In comparison, the majority of PET-positive patients relapse despite high-dose therapy.",
"   </p>",
"   <p>",
"    Although the goal of therapy is to attain a second complete response (CR), it is not clear whether additional chemotherapy administered after salvage chemotherapy but before a myeloablative preparative regimen and autologous stem cell rescue improves outcomes in patients with a less than CR to salvage therapy. A study of 241 patients with relapsed HL without disease progression on computed tomography after two cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (DHAP) randomly assigned therapy with sequential",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    in high doses prior to BEAM and autologous transplant or with BEAM followed by autologous transplant alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/27\">",
"     27",
"    </a>",
"    ]. The more intensive treatment regimen resulted in greater toxicity, but did not improve freedom from treatment failure or overall survival. A subgroup analysis did not find a benefit for patients based upon tumor status after DHAP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients with relapsed disease are treated with a chemotherapy regimen that is different than the one used for initial treatment. A new regimen is used at the time of relapse primarily because of a presumed resistance to the initial agents. However, retreatment with the initial regimen has resulted in significant response rates in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/7,28,29\">",
"     7,28,29",
"    </a>",
"    ], in particular, those whose initial complete remission lasted longer than 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Late first relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Chemotherapy regimens used for the initial treatment of Hodgkin lymphoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABVD (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      BEACOPP or escalated BEACOPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stanford V (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although MOPP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) and combinations of ABVD and MOPP are no longer used in the initial treatment of HL, patients presenting with relapse may have received them as initial chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A minority of patients may be candidates for salvage chemotherapy with four to six cycles of a first-line therapy that was not used initially (ie, ABVD, BEACOPP, Stanford V) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/3,7,31,32\">",
"     3,7,31,32",
"    </a>",
"    ]. This approach may be considered if the time to recurrence is long (greater than 12 months), if the recurrence is limited in stage, and if radiation therapy is to be used as part of the salvage regimen. However, only a minority of patients will meet these requirements. As such, most patients with relapsed HL are treated with two to three cycles of one of the following alternative chemotherapy regimens followed by high dose chemotherapy and autologous stem cell rescue with or without radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ICE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      miniBEAM (BCNU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      DHAP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      -containing regimens (eg, gemcitabine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed analysis and interpretation of the data with these regimens are difficult since, in some trials, the numbers of patients are small, the clinical status of patients varied, and extent of prior therapy is not reported. A large number of these patients also received subsequent high dose therapy with stem cell or bone marrow support. Details of the studies using these agents are discussed separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Late first relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, patients with a relapse occurring more than 12 months after initial treatment (late relapse) and in whom the relapse is confined to a limited number of sites without constitutional symptoms may be treated with conventional salvage chemotherapy combined with radiation therapy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Is there a role for radiation?'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Retreatment with the initial chemotherapy regimen has resulted in significant response rates in some studies for patients with relapsed Hodgkin lymphoma as a whole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/7,28,29\">",
"     7,28,29",
"    </a>",
"    ] and for those whose initial complete remission lasted longer than 12 months in particular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/30\">",
"     30",
"    </a>",
"    ]. As an example, one study reported complete responses in 17 of 19 patients with relapse greater than 12 months following primary chemotherapy re-treated with the same initial drug combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important goal for any regimen (retreatment or second line) in late relapse is the achievement of a second complete remission, since nearly 50 percent of second complete remissions will result in prolonged progression-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/30\">",
"     30",
"    </a>",
"    ]. Although there is an increasing reliance on high dose chemotherapy with autologous hematopoietic cell transplantation to consolidate a second remission in many patients with relapsed Hodgkin lymphoma, it is uncertain whether late, isolated single site relapse requires aggressive salvage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/23\">",
"     23",
"    </a>",
"    ]. Transplantation is associated with both early and late morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a late, isolated single site relapse of Hodgkin lymphoma after initial chemotherapy, we prefer the use of salvage chemotherapy plus radiation rather than salvage chemotherapy and transplantation. This preference reflects the relatively good prognosis for these patients after treatment with chemotherapy plus radiation therapy and an unknown benefit from and increased risks associated with transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Is there a role for radiation?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is indicated for patients with localized residual disease after salvage chemotherapy. In addition, patients with a localized late relapse (&gt;12 months) may achieve long-term remission with chemotherapy followed by involved-field radiation therapy (IF-RT) rather than chemotherapy followed by hematopoietic cell transplantation (HCT). The role of IF-RT in the treatment of patients who achieve a complete response to chemotherapy and plan to proceed with HCT is less clear. However, given the possibility of a false negative PET scan at response evaluation, adjuvant radiation therapy after HCT is expected to reduce the local recurrence risk. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Late first relapse'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Residual masses in sites of previous bulky disease that do not demonstrate activity on PET scanning may represent residual necrosis or fibrosis rather than residual disease. Residual disease should be documented by PET scan avidity or biopsy. Complementary radiation therapy to sites of residual disease as determined by these modalities may induce a durable complete response, especially in the setting of initially bulky disease, although a distinct benefit for radiation therapy in this setting has not been shown [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salvage chemotherapy followed by IF-RT may result in long-term disease-free survival for patients with a localized, late first recurrence. We and others prefer this option to HCT because of the early and late morbidity and mortality associated with HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"       \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Late first relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some clinicians offer IF-RT to patients planning to proceed to HCT who have bulky disease at relapse and achieve a complete remission with chemotherapy, especially if the bulky disease is located in the peripheral nodes or mediastinum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. As an example, a prospective trial of high dose chemotherapy plus HCT in 100 patients with relapsed or refractory Hodgkin lymphoma administered IF-RT to a subset of patients either before (18 patients) or after (6 patients) HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/36\">",
"       36",
"      </a>",
"      ]. Reasons for IF-RT included: bulky disease (&gt;5 cm), disease refractory to salvage chemotherapy or HCT, or disease that could be encompassed within a standard radiation therapy field. In patients with relapse stage I-III disease, the use of IF-RT was associated with a significantly high rate of freedom from relapse at three years (100 versus 67 percent) and a trend toward improved survival (85 vs. 60 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Can radiation be given alone?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation salvage is rarely used as the only treatment for relapse of Hodgkin lymphoma following chemotherapy. There are some reports of success in highly selected patients with favorable criteria such as long disease-free intervals, absence of extranodal sites and B symptoms, and the feasibility of encompassing disease sites in the radiation ports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one report analyzed the outcome of 52 patients with relapsed or refractory Hodgkin lymphoma treated initially with chemotherapy who were treated with radiotherapy alone for relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/38\">",
"     38",
"    </a>",
"    ]. The majority of patients had extended field treatment. Twenty-three (45 percent) achieved a complete response following irradiation; 19 of these patients remained free of disease. The estimated overall failure-free survival at five years was 26 percent with a median failure-free survival of only 1.8 years. A retrospective analysis was able to identify a group of 32 patients fitting a good prognosis category who had relapse confined to supradiaphragmatic nodal areas only and were without B symptoms. In this group, the estimated five-year failure-free survival was 36 percent and overall survival was 75 percent.",
"   </p>",
"   <p>",
"    Similar results were obtained in a retrospective study of 81 patients undergoing salvage radiotherapy for persistent or recurrent Hodgkin lymphoma after chemotherapy failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/39\">",
"     39",
"    </a>",
"    ]. On multivariate analysis, the following favorable factors for freedom from treatment failure (FFTF) were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete remission (CR) from the most recent chemotherapy",
"     </li>",
"     <li>",
"      Age &le;50",
"     </li>",
"     <li>",
"      Absence of \"B\" symptoms at signal relapse",
"     </li>",
"     <li>",
"      No extranodal disease at signal relapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subjects with three or four of these favorable factors had 10-year FFTF rates of 51 and 37 percent, respectively.",
"   </p>",
"   <p>",
"    A retrospective analysis of 100 patients who received radiotherapy salvage reported a 77 percent CR rate for the 80 patients who were treated with either a mantle or involve field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/41\">",
"     41",
"    </a>",
"    ]. However, the five-year freedom from progression (FFP) rate was only 28 percent. This low FFP rate suggests that radiotherapy salvage alone is not sufficient. Instead, systemic and, in some instances, intensive systemic therapy (autologous transplant) is required. The benefits of salvage radiotherapy may be confined to patients with limited disease who relapse after initial therapy with chemotherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HIGH DOSE CHEMOTHERAPY AND TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, long-term disease-free survival is uncommon following salvage chemotherapy in patients with Hodgkin lymphoma who relapse after initial chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/7,24,25,32\">",
"     7,24,25,32",
"    </a>",
"    ]. This is particularly true in patients lacking favorable prognostic factors (eg, limited extent of disease and a complete response duration prior to relapse &gt;12 months).",
"   </p>",
"   <p>",
"    Sustained remissions after high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) can be achieved in many patients with refractory or recurrent Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast to the early transplant literature, most centers now perform autologous HCT with less than a 5 percent early mortality and relapse rates approximating 30 to 50 percent. The only relapse pattern that avoids autologous HCT is a late (ie, &gt;12 months after completion of initial therapy), isolated, asymptomatic recurrence, which is treatable with chemotherapy and local radiation. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Late first relapse'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective, non-randomized GELA trial enrolled 157 patients with stage IIIB or IV Hodgkin lymphoma who had induction failure, partial response, or early relapse following initial chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients received chemotherapy with the MINE regimen with or without subsequent high-dose chemotherapy followed by autologous HCT. At a median follow-up of 50 months, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five-year estimated overall survival rates were 30, 72, and 76 percent for those with induction failure, partial response, or early relapse, respectively.",
"     </li>",
"     <li>",
"      Five-year estimated overall survival rates were 71 and 32 percent for patients receiving or not receiving HDCT, respectively",
"     </li>",
"     <li>",
"      Multivariate analysis indicated that \"B\" symptoms at disease progression, salvage treatment without HCT, and chemoresistant disease before HCT were significantly associated with shorter overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a randomized study from the German Hodgkin's Lymphoma Study Group (GHSG) and the European Group for Blood and Marrow Transplantation,161 patients with relapsed Hodgkin lymphoma were treated with two cycles of chemotherapy (Dexa-BEAM:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/44\">",
"     44",
"    </a>",
"    ]. Those with chemosensitive disease were treated with either two more courses of dexa-BEAM or high-dose BEAM followed by autologous hematopoietic cell transplantation. Overall survival was similar in the two treatment arms.",
"   </p>",
"   <p>",
"    A number of important issues remain unresolved concerning this approach, including the optimal timing of HCT, patient selection, value of pre-transplant functional imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/19\">",
"     19",
"    </a>",
"    ], choice of procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/45\">",
"     45",
"    </a>",
"    ], cytoreductive therapy, and the use of adjunctive radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, high dose chemotherapy and HCT should be considered as a treatment of choice in patients with a poorer prognosis, such as early relapse (less than 12 months) or induction failure after initial chemotherapy, a generalized systemic relapse, or a second relapse after conventional chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9396688\">",
"    <span class=\"h1\">",
"     RISK FOR SECOND RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for relapse after second line therapy include not only the patient and tumor specific markers described above (CD68 expression), but also the initial response to therapy and the duration of this initial response.",
"   </p>",
"   <p>",
"    The German Hodgkin's Lymphoma Study Group (GHSG) reported on 422 patients with a first relapse following initial treatment with radiation therapy, chemotherapy, or a combination of the two. They identified three adverse risk factors for",
"    <strong>",
"     subsequent",
"    </strong>",
"    (ie, second) relapse following various forms of salvage therapy, which included hematopoietic cell transplantation in one-third of the cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/8\">",
"     8",
"    </a>",
"    ]. These adverse risk factors included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Time to first recurrence &le;12 months",
"     </li>",
"     <li>",
"      Stage III or IV disease at first relapse",
"     </li>",
"     <li>",
"      Hemoglobin &lt;10.5 or &lt;12.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in females and males, respectively at the time of first relapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three risk factors were incorporated into a recurring Hodgkin lymphoma prognostic score; actuarial four-year overall survival for patients relapsing after initial chemotherapy and then receiving salvage therapy was 83, 66, 36, and 27 percent for those with zero, one, two, or three unfavorable factors, respectively. Similar survival results using this scoring system were reported by the GHSG in a group of 42 patients with early stage favorable prognosis disease relapsing after primary treatment with two cycles of chemotherapy and radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of interest, the first two of these three adverse factors had been identified as risk factors for second relapse in a prior, smaller French study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/25\">",
"     25",
"    </a>",
"    ]. The prognostic value of this clinical risk score in patients with recurrent HL treated with second-line chemotherapy followed by autologous hematopoietic cell transplantation could be improved by incorporating mid-treatment results of PET scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link&amp;anchor=H9#H9\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from two series including 698 patients defined the following unfavorable features: less than partial response to salvage therapy, three or more chemotherapy regimens, short first remission, advanced stage at diagnosis, and measurable disease at hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective phase II trial examined the benefit of escalated salvage therapy administered based upon a risk score (ranging from 0 to 3) based upon three factors previously known to predict poor outcome: remission duration &lt;12 months, active B symptoms, and extranodal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/49\">",
"     49",
"    </a>",
"    ]. In this study, functional imaging with PET scan prior to autologous HCT appeared to predict patient outcome. Normalization of the PET scan prior to HCT eliminated the predicted differences in outcome due to the number of risks observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88378862\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many agents are under active investigation or in development. These include combinations of agents already used in HL, agents studied in other diseases (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/50,51\">",
"     50,51",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/52\">",
"     52",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/53\">",
"     53",
"    </a>",
"    ], histone deacetylase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/17/37145/abstract/54\">",
"     54",
"    </a>",
"    ]), novel monoclonal antibodies, and other novel agents. Some of these are described in the sections above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Hodgkin lymphoma relapsing after prior treatment with chemotherapy are generally treated with either conventional chemotherapy combined with radiation therapy or high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) given with or without radiation therapy. The choice of therapy is usually based upon prognostic features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a localized, asymptomatic relapse occurring more than 12 months after initial treatment may be treated with conventional salvage chemotherapy combined with radiation therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Late first relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High dose chemotherapy and autologous HCT should be considered as the treatment of choice for the following subsets of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"       \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early relapse (less than 12 months after treatment) or induction failure.",
"     </li>",
"     <li>",
"      Second relapse after conventional treatment for first relapse.",
"     </li>",
"     <li>",
"      Generalized systemic relapse even beyond 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, patients with relapsed disease are treated with a chemotherapy regimen that is different than the one used for initial treatment. Details on these regimens are presented separately. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Choice of regimen'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy is indicated for patients with localized residual disease after salvage chemotherapy. In addition, patients with a localized late relapse (&gt;12 months) may achieve long-term remission with chemotherapy followed by involved-field radiation therapy (IF-RT) rather than chemotherapy followed by HCT. The role of IF-RT in the treatment of patients who achieve a complete response to chemotherapy and plan to proceed with HCT is less clear, although if the recurrence is localized and suitable for radiation we generally incorporate its use into the overall treatment approach. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/1\">",
"      Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/2\">",
"      Oza AM, Ganesan TS, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol 1993; 4:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/3\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/4\">",
"      Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/5\">",
"      Radford JA, Crowther D, Rohatiner AZ, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/6\">",
"      Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996; 14:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/7\">",
"      Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/8\">",
"      Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/9\">",
"      Radman I, Basi N, Labar B, et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002; 13:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/10\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/11\">",
"      Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009; 251:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/12\">",
"      Berrington de Gonz&aacute;lez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/13\">",
"      Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ 1997; 314:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/14\">",
"      Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006; 24:4116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/15\">",
"      Young RC, Canellos GP, Chabner BA, et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978; 42:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/16\">",
"      Santoro A, Viviani S, Villarreal CJ, et al. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986; 70:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/17\">",
"      Devizzi L, Maffioli L, Bonfante V, et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997; 8 Suppl 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/18\">",
"      Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/19\">",
"      Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/20\">",
"      Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/21\">",
"      Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/22\">",
"      Epelbaum R, Ben-Arie Y, Bar-Shalom R, et al. Benign proliferative lesions mimicking recurrence of Hodgkin's disease. Med Pediatr Oncol 1997; 28:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/23\">",
"      Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/24\">",
"      Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991; 77:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/25\">",
"      Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996; 78:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/26\">",
"      Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009; 145:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/27\">",
"      Josting A, M&uuml;ller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010; 28:5074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/28\">",
"      Fisher RI, DeVita VT, Hubbard SP, et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/29\">",
"      Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/30\">",
"      Viviani S, Santoro A, Negretti E, et al. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990; 1:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/31\">",
"      Bonadonna G, Santoro A, Gianni AM, et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol 1991; 2 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/32\">",
"      Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 1984; 101:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/33\">",
"      Byrne BJ, Gockerman JP. Salvage therapy in Hodgkin's lymphoma. Oncologist 2007; 12:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/34\">",
"      Mendler JH, Friedberg JW. Salvage therapy in Hodgkin's lymphoma. Oncologist 2009; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/35\">",
"      Wendland MM, Asch JD, Pulsipher MA, et al. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol 2006; 29:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/36\">",
"      Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996; 36:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/37\">",
"      Biswas T, Culakova E, Friedberg JW, et al. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol 2012; 103:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/38\">",
"      Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1997; 39:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/39\">",
"      Campbell B, Wirth A, Milner A, et al. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys 2005; 63:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/40\">",
"      Goda JS, Massey C, Kuruvilla J, et al. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant. Int J Radiat Oncol Biol Phys 2012; 84:e329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/41\">",
"      Josting A, Nogov&aacute; L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/42\">",
"      Josting A, Reiser M, Rueffer U, et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000; 18:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/43\">",
"      Ferm&eacute; C, Mounier N, Divin&eacute; M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/44\">",
"      Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/45\">",
"      Morschhauser F, Brice P, Ferm&eacute; C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26:5980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/46\">",
"      Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/47\">",
"      Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004; 15:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/48\">",
"      Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/49\">",
"      Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010; 148:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/50\">",
"      Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012; 119:4123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/51\">",
"      Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119:4129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/52\">",
"      Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118:5119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/53\">",
"      Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/17/37145/abstract/54\">",
"      Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30:2197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4765 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-3DB58A19CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37145=[""].join("\n");
var outline_f36_17_37145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9396345\">",
"      CONFIRMING RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9396352\">",
"      Detection of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9396359\">",
"      Sites of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9396373\">",
"      Residual radiographic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9396380\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9396387\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACHIEVING A SECOND COMPLETE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Late first relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Is there a role for radiation?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Can radiation be given alone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HIGH DOSE CHEMOTHERAPY AND TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9396688\">",
"      RISK FOR SECOND RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88378862\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=related_link\">",
"      Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7784?source=related_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=related_link\">",
"      Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_17_37146="Normal optic disc 2";
var content_f36_17_37146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54781%7ENEURO%2F80991%7ENEURO%2F59423%7ENEURO%2F72175%7ENEURO%2F52170%7ENEURO%2F60928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54781%7ENEURO%2F80991%7ENEURO%2F59423%7ENEURO%2F72175%7ENEURO%2F52170%7ENEURO%2F60928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal optic disc Grade 0",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade I showing the C-shaped halo of disc edema with a temporal gap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 354px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFiAcIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzd9wc85zTXchCTu464qST75wBimsPmNYXPdUewK5Kg5NNZie9L0OCaaFJ43En6VJqloPTI5OcGl5J+U4pEXIznOKMBWyByfeoNYrQUuytls8+9O3ejE596GGccZFNEZ8wAcD1qTVBlgRlmz6U8htvBP50Mrrn5efWkjbAAOQPWk2Wo9CSMsCVJ+U8017ct+8Q/MvUZqXIYZA4HvUqD5cjoai5oojYgLlCBncvOKfAkhfOSSO1RgG3mDZwO3vV9U6MowMZPvUtlKIiIwJ4PXtSyKynDZORmrNuPMGGON3Q0+RCsmR823rUXKaMWJvs04VzhW6E1bu4zJallycdKmvbNJUb6bkp2lSCWLyn6n5Tmm31M9dipo8rFJIS3J6VZH8KkkkHBqj5ZsdU2sMYOPwrVSIrPlxw3OaH3IasVLhQ7BDkEe9QrCwfamdy81evYwZdw69RUb5jk3gZbGaEzGUb6k1tZ+S/my52Y6VJNqRLGKEsFznJNUZLh7rILMMDoKrKC2Pn2kHP1qkr7mEi0sjvubJLDJrMu9zRyEnnFW4SRIQ3Ug8VXuUPkSE9cZxVrcyI9MfZAuTyORmtQAtas3TcRjmsixdTGgGMrzitfbm3Xnk84pS3NI9BFR0mZtxPHHPNPlkKybS2cjnFLIgSMO3ysTjimSNiUuMHjv1zUGqY4b1yy5z0xWPfSs90qsTnpW1CWYI4I4JzzWNqXOtgL93Ipx3NebQ2lmMdvEEPUciot3QHORTpEG9QDjaBn0qsysXJB6mpsa3sU9WlK27c9fesWRyLJVGQWbNa3iGRAkcSct1JrKkUloo2HOOlbQWhhVleR1HheHNupbPPvW9Gg3sG6LzmszRlEFmueGIx9K1xta2VB949a55PU6lpFFS7lWN1wfrz2rF1G6LPsDfIOtW9Yk8oe3TNZdhA9zLtPKqcsacV1KTHxwSs3mL0PAq15M2QMnA64q1PmNlCjjtikSX5WU9TQ2HMNS3Gws7H86BIOFXIHfNLI+4Adl/WmBCxPHWpKvcULkfKx96kWNydwzgcU+1iAxkjaTxVsqFDegpXBlNgUUnPTt61VaQscg8VLPIzckjb9KqcHGe1UidR7HIzzmoDIQdpz9am255pk6EICOvXrVIT1I5FKjBbtTH7AE1MdrpufGR0zTAd7cDHpTRjJET7lZeeKibe7naDWpBZ7lLycEdKY2wIT0Oew4qkzCSKUcOSA7HBNWCEhXCfMCOaSQEqSPu+/FQyMzKB0Ao3ILAuEAAyaKqAcCiqsguQPkSEdqVlKkdaG5YnFBboDyTXSzOKEIzjFDYLAA/MKUdPl/TtSFQW3dD61BqkOH0xmjjGTmlX8PenEgjAwalmqQAAL7UqnO056UxQxBz90VIisMjHB5qWXEnHznbgkikK5Jyox6UIuwjB696lJyw45rNm6Xch8kNnyyQ3pTlDqc8+hFWGUjlcZNCkrJlxn1AqbmiiQXETzDnjFPsrgqwjcdOOauxbWfjoemahurSRiXRfu9aV+jHbsXI42IDchT93FXkUIxJ53Dn3qLSttzbeU7YZexq22AdjJ0FZtikiv5AwBjgdKzpF+y3qgAFW5BNdBEEIIGScDHtVDWbYSFZB1B4x2oi9SGZesxl3Dgc4zn3q8jrJYwyP94DBq5cWEi2C3M4xH/DWXZgyW7Ip+4TwO4qr3RDRF9pklu5IVgYQou5Zj0PtT52UEHJ54qzFH/ozKCePWqbRs0Qz/DxTMGrFRGEbnbSiMuCFzmpBsXaWX8akRfLlYnnIxj1zV3MJLoV7iJly46t0HpVbc3mush/hxV6Q4gXcOnPNV3jxKDJjDc5qkzFox7mF7WUOhO0itCC83W64JyDyKmlRSWDLuDDArLlia3m3IPl9MVfxB8OqOh80FfMJJA7U0eXJjZzzk89KqBy8CA+lORgjgJz361nY1Ui65VIcjoDjOawgfM1Hd1+bOfatK/c7PRDzWXa43F+V4xmnFGiZvmUFT/tCofuq8hIVQM896jtlWRliBzjvVDxLeiMfZ4jj1FSo3djRz5Vcx7ycyXbPk/Kat6TG1zeqzck1kKSWC9z1rr/DVssUfmMPmPt0rafuoxpXlK7N+CJQNoxgdSaf5u4tsIyox1qNGBUgD8ap3NwqMBHjd0rlsdq1M/UJWeRlcZCn9a09FgFvavI6/O3aqFsgluPnPyg5OfWtlmGFxjC8029LFPYhKlmP6Zqowy3H3e/tVmaVSuUPJqED5FPc96QJDAMMNx4qZSOAo79+9PcKpVQMntTnURwlm+8elIu1hqZUgEjg0lxOWGG4Ht3qssh3dDu61I4JA5xntSsUtUQzSM5yFAUelRx7SxJqaTaU2+naoWTZ1HNUiJKxKDkZIAqM5J4yc1JEplJ4xVho0ijDDk/WghsoLaA3A3nap7VcZoYVComSe5qlPOd+5ckVLArTyDAx61VurIbRbG4oDyR6VQupNiFVVR7Vbvm8teOMd81jSuSdxNOJhMSW4lYckEDgVF9pwMN0qC4ukQAAjNVDdhzgDIrZROeUkjWWVSoPtRVNJodi4HaiixHOydjhuBTkGSO3rUecHAHA9TTlbHXpWzKgx6bcELTigbBqNflcVPxxioZ0Q1RGMHNIF8tgcDnvTwBnnrQys5GB0qTRIkTd2HWl6SkDuKZuI6Z6U6NTkseRUM1SF7/XvVlFG01HxwAcYqRXG73qGax0HJGBwCTnkGpFXOCe1RhsHg1NHk55OPSoZqi5FEXUFCMjnHrU9rKsb4fjnkGoLQjKqud1WLiEsAT+DCoYn2HXERt5kuIl+XrxWgv+nxRsqj5RzVS0mDp5b4ZajZ20y7+RswvU7ha5qwWuSxB6fyqtqGIo13nC5yTT0uy+SCACPzFV9QQPCMHIIoRFn1HtcrfWrQl28tAce9Y1uRb3RwSQ3H4UuluUuniI+TNJqK+Rc7gflzuWrS6EtWLVymzKhsk+lVp/lXaCT06VfmUGESN1OGU+tUSwkmEi8jHQetNHLNkIw3ykCnplp1JK7Twc0pTMm8gjPFRxIPPG4HHtVmDFvBtlYAYGf0qldKHVOT3xirN2SG+YcnOMelUixSEbwevFUkYsCSiLxkAflUN4RJb5B+YnipZnyQRyuOag8uS7kURjhOTVoPQsxxmKFQ3LdqYg3uxPBAqS4bL7BklV60y2TdG+/g+tIpaDdWnURCEEBjyRVS1T91k/xHNQzyB5cnJGcCpw/wB30Ap20KvYszTiyt2kB+ftXLTSvPKZX5zVvUJmuJyiHIHFVvLJYIAfStIxtqRNuWiLGk2hubhcdCa7WJFgVUXlsYOKx9LgNraiUfe6Zx3q/BKpyXfoc1jUfMzsox5UaN3ILaCPceWGfwrGk3SneO/3aS5mNzeBc5UfyqaNcsTjgdATWaVjoiWbZPLUEcg9frThKTuDcmo3k2oMHr2p8eCpyfcmpKsOkUAqcg56+1OwQuSCB2qIYbLc4HvUiHJ2tyM5pGiiTxooVZZTkkYAqCeTzF44zwKezb5CP4VoCgvu6Y6Uh8vUjhjAXLnn+VLImRuBwKSZgDtxyO/rTYiSSp5HpTDrYhZvvDPPTmkGeM8+9WHiULlu3aqsp+bGcA00RLQmEyxDcBg1VlZnILZpS43AZ5U88VbhSDli2WqloYSKix5fpxVyBwiuhA4PFSOYI1ypXPcVkPck3DZ+VaNzNtItXUgcE5AAFc7eXG5yidM1dvZix2p09qrR2wDBiO9awVtzGo29EVlsywLvkComtgclfpWw+ew4xVIrlyVGfTFWpM55RRWEL4HB/KitRc7RxRT5mRyIYcAnPc0Meg7e9BALEjrRjBPetDVCjlgBzip8jCnJ9KgQlW+cfQ1IzAg4ABqGbwHh9z89BUuewJqtEpwSeTViLls44+lQzeLDByemKfwFzznvSBCkhK9OtTohcc4qGzaOw2NCwBPSrAjyMg89DTVXONp5PPFSKCMk9qzZqkM8sqOnGKfAAzDBwKemXGD25pQiLuK9cfrU3LRo28W1wyd/TtV9oS0IHc84qlpsuwjzOR0zWnO37s5H0NZN6iaMxofs05J6dx60k2yWJo3PPbPapLlm2bm5I6+9R2yLNGJW4I4I9RTEVrC48g+VKDj+E1qBg8RGM9xVc2aXG4K43p09xUNvM0M5icHIPGab12HuV7dBBqJR/uv0J7VY1aI/ISdwXg1Z1e2V1S4gPvwKY0q3VquVJccH3p36mb7lV3a4sdqE7ov5VXtBmMqOCOv1pkM32e62sMgnnNW9qocqMg8jHerOaoQF/MjYrkFTSbs7F5zuOSKjjcv5xAIBOKVyZQjcBgecVVjmZDcyAsCx74pk0ZCjB+QjIpJkLMQBznPFTSRt8qKCc4qrmbiZdxvUbQ2D0+oqxYHBPltj1qvdfLdqpB+b+daC2zYyPlHfAqm9AUWV5V2uz7uh6VBPM3lHaeW4/CtFrUuGz3HFZk0QaYJz8vWkmWosqRQtkcZzTrrCQMvIZuBWpbQEMGIAUc81lXjh3Y7c88HNWndk8vUoqhSLP8fritPTbXlGYht3YDpUccElwY1xgZxxWxFC0a7cYIGMilKRpTgI4wzRk7VHIHaqs/yMNvU/rVsoNhYdahtYmuJh6Cs7nXGI2GJ48tjJPU1NvKoQoy3Q1bkj8tNuPm9c1WUEgt7YpXK5RykkAHpiplycL2PT3qDB3jOcCpg+1ge4PFQzVLuXBCrWrA4UnoarRSfO0Y+8vFMmmeQ7VY+9Nt1wz84JNKxoiycquASQeac6cLgnpzSgqMbjnsBQ7k7RnApA2NlUBRjk9Sc1GThxgio5JlL4X86ryy+UDllBqkjNlpnJ3Ljiq8jpGgLsMjrVSW/C/LH8xPU1WEU1yGNWo9zGU+xJLdxhz5fK9eKja/Jb5Rg+tSQabg5dsA1YSxiVuozmq90xakzPxcSy5LHB54qXyHdwpzzxgVrKEXjCgetJdAwqphUAg5LU+a5k423K6aeV5IPFQTxGNuauJeMMktn2NVWkMjEnoe1JXFKxAxAjPHWoAhB3jGKsN8xORjFQk/MV6DsatGEyQEEDrRQsZ2jntRTDUbld2eDS8FuB1rMWd4m+bkVoQSpKcqe3StpKxdOSloTMMgDnionB34/hFT/wnB5FQp87MazOiwh3cH9c1KjELxyfrSbSFIUfSnxRkqD71LZcVqSQsWPzflVqANvG0VAqdM9KtrlFBHesmzogu5InBzzkGp0QSOMAe9RKC8ZytTRtsGCPxrNs3SuJNGSpCcOOKZEkrIQwz9KkVyzs3QH1qxCGDHkE+lTcqw2FCeAMEGtaNWkXDZxjjFQwRuVI2g89R2rSihdSBuXZt6mobFJmBfI6bVPTOKfFlAExjPQ1amXfNg4OCQKi3FvlIGVPQU7ktCQkFiyDDrwRVl7dJ4PMQZlBwKiI/eM6rgn0p1qzxB++eaBFS3uzHvt7jj0HvUDSfZpgw4wc49av38C3I3jCyZz06isK981HIYEgDhqqJLV9hdSkR7rco27ucD1p9q7ACNiQuaoSyeagBHzAcGr1gUkCqeXA5rTZGM4aXHP+4Ypg4Y5yackJYMOR3B61Jcx7wWcEbafa9ecsufzFFzncSsLZl2nIYk9K0rWwkkEDNwc8n0q5Dbw4V269QPWrUb5gUqMFXxj1zUuTJ5bHNeIdL+y+VcodxHLD05qxHia3WVD8jdvfFdJfWonD+auSy4I9q5rT4zY3bWkx/dOTt9jVJ3Q0rrQf5IS0diMFeeazLGPzGaQ9eR9a2ddBhsVSMYDN3qTR7MtarKV5UZ4FCelx8tomNrUYsbIA43P29K5VAzSA9q6jxareaqZOAMkY9axtKgL3USHBya1g7RuZ8mqRsabZOIEAHOc1o/ZtqEYIU9DW3bWgjjHG0djUcsbpA245Q5+Y9hWEpXN4nL6mqqFSI5YEZxWpY2gjjTK/PjJqjptqLzU2OcKpz1rpZYTGijPXvRJ9De9tDEuU3NgxgE9+9VxbFWy4wvqO1alwFWQDaWYfhVdmDKQY2HfNSmaxRnSqFBxyPWopCQpHXHrVhlOPlUkk9TxVWaKTcS/6VSKYiZzhPqalikAZtwwTTIiFGF6+tEpDxZHX1FArk24DB5OKp6lqKQkIgGcdPSobq4aJdu76VnWsDXVyWbOM81UY9WZzk1oiYTTSsSM81ItpNM4yDz61qQQIq+WvIp+RFIBnkCjn7CcdNSpb2CxHL8sBkcVKFAzxirCbyjuccc803jYPUnNJsVkiNY3l6qcULDgEnAOelSOxXABxj0NRO7Nv2/xU0YyYZCBSwwvJpkl0rxMijB9qrzyZO3nFQ4P4Vokc8m7jC2TjJFI2d3+zTXUq/PT604gk4JxiqIYnT5s5HpTSeAO9Sfw8iox8/GB7GghoeBwMk0U4IcD/AAop3J1IJ7PO4p970rNdWikyMq1b+4gsT1qGSJJ0+YDNa8xp7K+xnR3rBdsn5ir9vIjphSKqS2Df8s+faq22SFhglDSaT2LjKUNzcVDsJIpC2MDPNZsN/InD/MOlWluIp9p3YYetZuLOmM4yVkXFfGB26VaUq0YHOQfWoIyhHUHNSLhGxjr39KyZ0Itxk4x2NP3Ae5qtGxXvxVmMgkqOnWs2jaDHxtkhSOp5q1AiiXbnIPeohGuSSeBVyC3VxuVztHXNZs0Zb0wlZCSD16GtnVLuOaBIxEI9qgcd/eslLuC3G6Mbm7k1Xa6adpHYHAPy1O+pm4tu4kpAbKNw3UelIpGDj73r6UhOAC6ZFNxhlYEYPGKYDkZlJJ59R61LasGU8YZTkfSoQ3zlWXj1HapEbYdmeM8EUCsSyw+dNydpPTFZ9zCwyh55wM1dmkYFdp+n1qKR98YJGCTkD3oQloc7fQPb3CNt+RuPrSREwThwfl7/AErS1lvMih45BxRHBHPGUI6jJ9Qa2T0JfmXINsttK/BHqKsWFp+53ZAGemKydLlNrdNbynCHgGujty0PyNgZGVqHoYTjYkt7dZNwUY2kfhVuztlechuCORipLWBvMDgZHU54q/5aRyMyZjYYIHXNTcxe5X2MZWWX7/8AMVyGvpjxNDEVII2gAd670W8cql5cEqCCK5LxRZrbXtrdxkttIGT7U4PUqlZuwa9HGttFHIuG+8B3rS0uMLaRrERyuDmk1dkureGSQAsy5XAq/o8KeUmQdoGGx16Ur6DkrQTPPfG+W1EkjBCgcVR8MRB9TTDA4PU9q1/GqeXqsg2n271S8FR/8T1CBkf7VdCfuDUep6BJttrYBow0jcKM8scVjavBItm7MSG28jPAroIojd3byOSBD8qY9fWsvxRJ+4Mbghvu4ArnT1CmveSMnwrbKIZJHA25xW5eBEgZ+DnhRVfQ7YpaImCc5Y+wq5DbtcyFznyEPU8ZPtQ3dmkvibMc2uEGSCSetRzQqo2/xgfhW9c2yorELkds1yeuaj9lkMVuAZD97P8ADQtS4u5NIkSRebLwCOCeKzri4tnBVZkL9zVEWF9fqXkLFB3Y8VA2kCNuXJ9fetFFLdlttD5ZY0yA4zVOe76JGMLVj+z0R8EkimPaLvznIq1Yh3KBjecE7j9at2ceyLahIA5JqxHAFG3P0NOXaCwTkDqTTbuRa2pNFMEIHr37087d+4gn61EhAHHJ7Goprvyc4IZ/Sot2LvpqW5pwPvkKh4wKqSXkaNhBuqliW7JPNWfsW0AF8Z707JbkO/Qilu3Y7UGKaZpNrcjp+VWGs1BJZ+M9aFt0KkkZHrVXRjJNmcs7A4yN3qasR3CgruUH1xT5rJCMAYqibN0Ztj1asznkmmacQt3wMgtnnNF1AoY+WVPfGelZDSSRnEg+nrR9oZTvVt3t3p2JbsXZAR26CoC5XpiiK5WXhT+HpTjG2OhPfimZyZOp+UfP2opio2Bx+tFFhXY+XPY8UyLcp55zUrLnpjA5pyxFwPSrbOpRdxy+h6daDGkhIYBhTBlGI71OjKVGADnrWbNo6lCXTA+4xEDnjNVZdOuI+qHBHUVujacKe1TJI2zBwQDwD2o52ilRizl0E0XGWX61Y+2zRrywI6c10cqxTAb4lIbqaYum2MuUOVak5p7otUZLZmNDqjheVBFaNtqkL/f+Uj1p8nh5WGYZBiqUmkXEakqAy9Kh8kjSPtI7mzDdxysBkMOvXFXReL5YVCIlPXmuP8mWNsbXT6VNDEHwJTJjoah013NVU7o6M3kCrh5QefWpI7+3xhZcHtzxXMvYyBiI42Zexp6wTp96AnjtS9mu5XO30OqinDJuEgZfTOamBByYiPUg9649J3jXC5jOelaFlqD8CU9+tJwaJumdHAxMxDAdM/Wl+6c8BM8H0qlHL5jqQcnHbtWkirIRHIcJjqOorPYNhzBY0Ikwx7fQ1UYYwD17VMRschuccA1Eec9vQ0CsVb1d9q+0fOh3VZ0/ynsUlTmbO01YtI03M03KsuB71Th3add5kVvs8nH0qt1YjfQdqOmvPF9ojB3Y7DrVjSbwyxrBcfK68A+prc0u5WEnCeZbycAH0qLWtGimBubQhGByFHpRfoyFJN8si3ZTSQs4HzLtxzUioWKux57gdqxdMuGSYRXO48Yz71txvGVIGSR97PH5VLM5wcWWcPGjBj94cH1rO16BrjTOVyyfNkjBIrRVxwsh3Kw4Penu5mt5IyMgDoe4NK9iI6NM5ewZ7y3t448kxnb9K6iKAxYHRRwcd65Xw64j1YwsSoJ+XHqK7fUkUxBs5OMADqKbdma11ZqJ5p4yAOrEoQcgVU8NuLfVleTkHpirXinCaswx0UdKo6Flr5iDWq+E2jDQ9PsESOyUupZmOW9jXMazMb67WOEbgpxn+8fWtDUbtzAtushQhQXZT09BU2laZ5afaJiRI+No6YFYrQmEVT9+QyzhuUhZQqopwpweuPSteCNWtgDwoHTFSrGTtQkAqOPX61PFatDC25wTnuO1Tc5pyuZWobEtw6noCQDz+dee6VZi+1zM43oCXI9a7vX8Q29w5OPlIAHTNcx4WhLX00mOQAvFXHRM3pK1Ns2tStEhgU5A3DIRewrF+yhl+6FGOhrorpUDNnnHY+lUJgzgbBhe/FCZMZM5a9jWMYHJNUACck9K6y805XjYjaMCuZvB5chCjHr71pF3LvcrykHnPFQLGWDAZIPJp0sbHODThMsEZBXJqyPUguLny4tkYGR1PpVGNN8hZz8ppJ2DyEr0q3CAoUkZHtVbCeuhYhAVAqDApxJY5YZwaGbdhYxzSthVA6etQNj1G5csenamnauNp4Panq4KADGPU0kgVCDzntigiVugpZZV+c4boDiqjoY5juxg96tKPur/ABduKluI02YI+Y96q9jGS1Me5QMwJIPPaqlxbbsNHwRWo8ecbQOPWqs3yk5zWkWZTXcylG2b5+D6ir9tMJH2sxU1WuIy5OR1qumVkCueB0PpWlro5m7aHTrEu0cdvUUVmLLJtGCelFTYdwzJGT1zTo7plPIq65Bc8DrxUsdtC7ASDk+lNyXU9CMH0KDSh23Ac4qdNrBSGAPepzp8e4hWIFRS2bR9DkVDaNVTZLGVL4GM1Y2Ajt9RWWAyPgqfr61IHlRuj4Pv0qWjaKNEIVADAnuDTtmdxAJFUfPkKZLN+VSLcSY4frwahpmySLSPjHUc1cR3IGCTnqDWV9pkxglSKvQXyrsDIDgdqlodrmnGIJEAkhBYcc1Zg023lQ4Qbh0wazo7+F2AIKkeorU065tyTggHH51DujKSe5dsdKjkTcFyAeQtMu44nG0RqvON2MGpRcylGFowjJ9D1qvI5RVMgLjHJxUEq99TLm0uKQ7J4xk9Grn9Q097SbaMtF6iu0uLhDAqdxyDjpVR7YXVuzLz7d6qMmjbdanNaddG3lwfmjPOe4rcgnST7pIz2Pesa+tZIHGRn3xjFMt5ZIzsJyM9K0avqhLzOkMh24xnqKIYzwCQAT0NVbebzdhDg7R8wPervmhcHKnI6D1rITJ4IxGjLt+UnnPY0PaieIxy5ZexBpY3aaDKHJBwVPpVm2jTlWJ/AUGT01MmO11TSn32w8+36lTzx9K6HSb+K+jZT+7lBwyegq7Zo4TORtxg5rD1q2TT71Ly0kVct86+9O9ybqej3NK+0x5G8+0+/wB/Q1Vt/OSNhMMEe1bNjewSxLIhU7lzjPQ/SrkaLLGcQqZBxntipuSqjirSRhx3yZjWRPm/2eRipJLqGJn2OZHYYb/Zpvkbr8wvEqPjLbTgAetZepyWNs7broFxwMfMf0oNowi2UrkrbalFNG3zZDV1stwZERWPBO8sK4V9RtZJlI3MR3I613dtr2m6jpywraojqAuFO059fem13LrJ6NK5594rO/WGAbnHNQeHpFSabA529fSn68wbU7l1zlffNR+G4vNMgXrxWr0iaRj3OptlMsnmsCEQgjPc10EMrmFjIM8cHFZDsi24CZCYxxU9vM8gjLEFR1zXO2Z1Fzam5ZEHaf4gO5qxLN5gCowXB5NUCyhlwBgjPoKZJITOCGATb3HFScrp3dyj4slCWSxZGX7454qj4Xtj9kkmxhpWyBVfUnk1K/jjDfLnYMeneuit0jsoIo8hVUYAPX61b0VjWUeSmo9WRPBvkbd97FR3EI2ALjdjOB2+tWRcQoWAMnlseWC9acyIiKxxtbv1z9aVzCzRzt85VRGcrn8jXN36L5vTGDz9K7S8jG5mZQ4I+XI4/CuX1OBncgDBPbFaRZrF3RhmMMxJyEzVDUpVICxZA6c1cvX8kYBye4rIk3PuYKcCt4omWgttEGbDHjvV3aiHAbAziqkEwRAOg78daEkVpPkQ7O59Kpq5kpouq6puC8nqSak5zlzye1VISu5xK2R2AqdXXG0DIA9alormHnfxwDtpyAyck4HpUDNt4ydx7CmLOW+WNTkdaLENlwn5s96sHMqEk8mqcaOT83FXXZREOuCOMUhMpschuvoaozLk5ar025fuDr0JqnLjbvBySOauJjMqSqMe9VJEIODVmTJcbT+dQSDc3JrZHJLUhCyYGGb86KuqDtHB6UVVyDXKqeoqRNoccnI70zcDxT9+B8wxWLPbjYspgnkgj1qGWQFsLzihnBiLY+hoto88k/Mag6Iu4QxknLCrKPtJBCn8KXbtHXr2qVIyFBzyfWobNEiNChO1kU5q0kNvIg3JhxTSgQLuGe4IqRQhO45HP51DZaQyGwgfdwaQaZETlcg1OgKuAHIWrFu5XO7k9MVPMwaKcGm5fhsY9K0LfTXyQxRh7jmmWbltyugBDcHNaAZgdwGDSbZnK5z0/wBotLpthdY88Gp4dWm2/vPmT2rZuoEl+YgjA5A6VXl06z8lcKwc/jRdPcSa6oqR3scoAY4+oqeGcQD91tdSMkDmq0unDBCP061CljcIA0XOP7tPQtKLL11MLpdrqpA747Vh6lZuoDQYKZqdLp0kImBIPHpU63CgY249jTjeInAzFle2K9Qe4NTi+KkMPyqy8cdw37zCvjg9jTVskl5VCwPYHke9VdPcizRCNXkiO5U2n61FN4ivmBELbOOqDmr7aSZFUDKkHk4ra0bQoRkTRbyOjUXiiJWW5x5v9WlAAmmO7/ap62t7J9/zXI+terWthbwxBfssZYeijIq9FbLs+VMEnsBS9ouiM/rCj0PHY1u7dsq7qwOMZrYi1vVYk2rOT+pr0ubTbO4AM9shYdcrg1z9/oNnNerBaqIieZCpyRS54vdFwrwno0cNdXl3NJunnY5+8QetMjgaditvA8jY5Y8mvR7fw3ZQLtaBZABne3OatwpBaIyiNQp6YGMUnUS2NPrEdoo8wk0LUVUPJbuq4znpiq8Dy2zhXDhgevSvRLsANKFBfPf0rAvreNUleUKVRS2aFUb0ZrCXNqzkjPvnu5GyflPNaXhUna2cYJ49axHGIpAv/LQ1oW++xtYTgiQjIrWS0sON+p2afISnVeyjvU9r8ygY5NYGj6sty/ly8OvAPrWzbzMQSB1OeK5mmhSWhqxzFSMAEDjmqmrXMflhARvblsdhUU1wIELTkKT91f4jVbTIhd3bSy5KKcv6ewoStqyIwS95mhpdgreXOWKl/ugDoK30sYoEzt3u3OWOSKrR5JBOFA5GO1XYZY0TdLKuewY4qWzlqylJjynlnDg89j0+lZF1aozObcmNj2B4FazXQlQyF0EY6c1k32q2qZHmojD05oRlBSvoU57gkmNwN6Dt3Fc7rd6kcLcAEggY60/V9VR+YSS46PiuXljnvLgvK5KZ6nitoxOlQsrsokNcO25uOpNRzlRC6LwtXrtY4lwhwO9Z7AOc4+Ud810RMKjuZy5ZtuPlBq5DjBK8U3ZslIA3AHpVuPYEIGA5P1qmzBIjC4PIznvUgjUHcpwSOVpxTdjPbmmhl2jvUldR6R87uSanjADAADNJGpK/KwxS7QpOWGTSuVYDuLdxmr0TAxgnoBVWIqpz1PvVoNE8QaPBI6ikyZMp35bPy9qzZi3TOPY1evnHPzZP8qzpCSCR26VpFGFRleZlAAxz1qFsDGPwpJQSGJOKYSVXk5rVI5JNssLIdo+btRUSv8o4oosKzN0MpcHJGKl35yMA46E1XVTv2jOTUixknA6+lQz146ks0n7tVAwe4qW2AJ5J6VXdQ2F/i71YiwowOvc1mzphcsxNvA2qQc9xU0m8JGVYYzzx2qABsgLxxU8TljtJxjqKzZ0ImRQwyRyKmcfIAqfLUC5zkHp2FSRzOvHr61mzRBCQDjgj3qR8eaGUYHTileRGjA2jIPOBSCeMLsZee1ITRaa3+ZGOMt6GrLqPL2vlVB61mxuu8t5n0Bq8k+9fmIYYxgHvSZDRKBsVWY71JxwaSVSMFN6E8EGnbgu1GVQnXNIzjOSd3pg80ibEXlPwyPhhnNJDK0R+dy/vipncKm7ble/PIqIzRlSGOPSmILmOGWIysqMf5VQms4uNpIY+lWSQvmK4V16gqagdgrgIpXjOT2popJrYrzWMqAbRuB6YODTbeV45FTbnHUngirDvu3biSw75pYg7kJs3ZPHHNO476am5Z3ULxYdx5nT561LNwHYPhTjqDXOrp6zKyo5Q5yQ3QVp2sF9Yn54/MUjtyCKk55wi9mdHZx5YMHbdjH/1jV+LMYwMZPr0rAstbRU2Tw4fpkcGtS1u4LhAFfA/uk8ipOSpTkt0T3tybe1aV8egA6k1Bp9qVEk0gUXEgyDnt6UasplS2jXaVL54NLOv7ol42DquQSaaEtI6dRzTOpdWX5sdRWVdSZBVetWbT/SIt+cSDjrVeYLuKn5T60rG0Fysz5JTIMthWHBrC8VTi20ZsYzM2M+wrYuUXzmw2Qx5HtXLeOmM0MAhDbEyMEd6qCvJHYlZXRzVk7XE8cSjJLACu7u7KKaERH+BdufSuF8PMtvqUU0ynajZIFegxXFpdhhBLlu4bitKqaeg4TujkrO1eHUML1B/OujvNXS3xbaem+Xoz46H0AqpKgsnlkmJDHOwVDpcot5TcHEOejEZb8BRLXVmsYqRfh067cifUXNujdS3MjfQVow6ikCCG0tSsYHG84J9zVaFLq7O5gYY2PDucua0INMtlBZg0rd2c1k2hTcft6jf7ScNscQJnncSWxUG+9u8rH5kyf7uPyrXt7azU58oKenHU1p2ixlPkdlHvxU3RhKrGPwxOZj0a/IJk3onX5mp3/COMQxnlwp/uc11Fz58hQQshQHBZv8ACnTxPhTwx6HaaOZmEsRM4u70qytVyN0mB1asC+dR2x6DtXbahasrFQnTqe1crrcUcYO+T5+gA9K0i7i5nLc5m8xJgcYqjM2xc547CtCcopyPuj1qhN8y7sYHXmumJhNjISzgkrk55NJ80chwMkUyNwX3Z2rnoKmnZeWDACqMriLNuHAPvV2MbEHAweuetUbSaJlIDZf0qykofG7kg1LRcWSfIWPHPrmpdpMZIAJz2FV2++vAG6rKkcr5gHoAKkq4+NWJ+cE59KkDLGSp4A64quhYPx1NSiQbcBMsPlJpmMzPuyWbJPHYVVcqF64qzduO2ARVJmU8gDcK0iYzKkzBjtHINRkYyCR7U8ku5bGD7UyXO3IHNaI55DgRgfMPzopgBwPkNFXYzudGrqrfN29aVp90nyL+NQ+V5hLNUqbVH3SDWLse1FtDxGSdxP5VaVfl4yKrIeOOKnU/NlmwMVmzogy0WAwM5NKjBuCOag3471JGX4PAArNo6UyVWCsdpP0qYPlc45FDOSw+RelLjaAQy/N2FQy7jliLnlgBS+WqsMNn3pI1A+7nPep448DJOBmpG2O8nI6rx3xU8cKkH5SGxnKmkjAD7lyynqDVxSvl/u8rntSbM9RIY5G+UPyOmRUGxnzhjuB6VPGEkQ+eXXscHFEbQom2MEDOATUg2yrJGyggMQ3YetLbxK6lpVDEdvSrzIjOGK9e9MaIISQuSOhqrkc1yCYQRoCqAEcVC0Y8ksCfw5qZ9vlkt8zZxiosxspwxDD+E0DK5tklBYOFYds9afbxXUW7y9joBndnBFLgIMgKWPJNWY5UaLDrgUXE2x9ub1jgW46ZJJ61q2+pTW4G+CRivPriqllKy71XO08e1acBCHJIORztFJsym090Rieyu33ShopOvzJgH8ad5EKufKkOCeFHI/OtNIhIMIN4I53LxTTFaW2JJVXPY44NFzJVLaIzfNuPtKIN/lxHO4dK1xqTSoSTEx9DkU+1VrmYs3lomMhVHSrjxQZO8qR6AfepNkzqRbs0ZwktCAxVoHB6g5BqOW0+0NkSbxycirE9taSDMbupP5Gs67iuIlJttu0jkqeTRcuCTejsJcxYchAoCenc1DJFbXUDwX6IY2HUDlT61TTUJomCzJ5i5wRjBFSebBOrbZdhzyGHSlqjpdOSWpyOqaDJYys0eHi6hkFUFItmD7SZOoGe/rXfuTDZyzbhJgYAXkGuOa2fU79iPkGfmY8BfpW8Zt7lwhzJspvdSXEgd5C8oHLN0X6Vv6FFbhRJIN03Xc/OPoKhbQ1iG+N18sHv3pNjSTRQJ9xerA02rol1lflR08IV1LDceeoFSxcH5uAfuj1qmNP1C1jV4pDJH/cai11m3LmK9UxSDjn1rnaFbmV46mxDHjdubcGHH+zVtZkQAFdwGBnFYb6tZoCd/wAo6Y71S/ti5un26dAwH95ucUrNmfspS3OpmaNsMN0e0dMcGoHkZ0JVug429Kw44tTkB864I9hUEsepo+BKXXHQimokeyXcs6tfmG1b95mXqBjmuUa3a7DSyht5HGeK2P7Oklk8y4OWHbOaguozF8ilevatI6bCdkrI5ho1X7+CAeprG1Odd+yMZzWzqKMJXIYKAa524KQk4cMx711wVzkrSsQjfkjIqUlyAHaq+8kg557VPFhgSeDjitGYxdwX90wkAzg81oRyoyAqBuPaqUbFo2U9PSgqGwInx/SoepSdjQa6jEZX+KoVuLgphUXHvRb2ix/MxyT1zVoEIOTU6LYq7ZXs5nkwWyDWvdTCOElgAzCs6zKre52ZXqBReSG5zuBAz0oauyCtcTKzHlc1QmfCHBGT0qy0cOSpBB9ajaKILkjnHrWi0MZalVVZEyDyaaSc8nipSR2GKrzEnv7Yq0c8mWBuwPu/nRUaqdo5FFMm50Cnk7T16UHO75iPeoiwLcHAzSnIY88Gs2j1lInHTg4x0qYN8n3R7H1qGNxgA4qVDnKkHFZs3gyUNuGcVOASgboO4qqpZSOPlqbzCcDcR7GoaOuMiz0QFTn2p0Kbm5IGPWqqP/Cw+lTJIQCOMdazaLuaCsm5D09TUzHaBknJHaqSSrtJwd3pVwSBkRipB9T2qGXuWLWX+Ex8YqUzhpAgOCOlRKm5Q4AGT61IuFH3VyO9Q2NIZKsmGyTUaswULu4NLJK6uuJDjuDTldQQcbge+OlMTiS7pUXHmED27U+Of7ockjuSetMaTHz5BPpTZZFBXPy5HQigzaLFxsBUqOCcg1UlXJLsVH0qXzFfGxDle5NULmJ41PyE7j2NNAl0Ysnl7c7uR6Uzzycbl6dzTVgkC8j8zUQXDfKwb1zTG7Gpb3YAw5Gweta1lqkUasse44HpXOwynGzywM9z2rTtpAIzhPo2aTRjJJm0NSuPLUQxuATj5+lXbe2lmAM0qsQdwQ96zYpTIEAC8djWrbygESOhJA5x2pHPPRaIvwIsU24AgAcg1Kz+eu5tie2Kow3LGeRyCseO68miaYySeYpI28FexFSzFR1J7iNAgBkX1wKy7lXwAOQO4NT3B3wAkDy15+bjFYd34hsbXKGQy+yDAH40JN7HVSjJ7F11RyFli8we3X86hfRImV3Nw8EWOTJjj8a5668WsE2WcCKc/fbk1lNfXd/IRNLLJn+EZwPwrSMGdcYT72Nm/wBZttPiktrNmucjBPQVyr63dQFvI2pn0FaUelvdHcT5UY6nuat6XpFjcQ3JeMu0QyAWxx61acVuXKNk7GCNcvpiBK25a7bwParqd15k4yqkE1yN/bQQKfIGHHX2rtfh/PHBplwwP7zI4qpSstDjqQfK31Oy1V44dqDgD0rnbyztL5t0sIZv7w4NS3F+XzsRpXPUf/XqONrhjyUjHoOa52+pNKDporx6TZRyL+5LY4wzZq3CuwbAAijoOlNWJhIzByzdwSKtWqsxABAPbIzUsqUm92SwRrnL+3TrUdzblp3x0XBAI7VoRksjATJuB5O2oLmKRlyZQxH8SLg0kc/NqZF7FJGSRhuOwxiuc1dnw+wc+9dFfwz7dyNu98YNc3eBsYkcA+nQ1rAaOP1dpUJJBPHOa51gT1FddqaGQbTgjtXK3C7ZCBxXfTehwYlNO5Cp7EDPrU8TYwR+VVycsMVYi56nmqkKlqrFpe5HTGaWI/N0wTTIiShJqe3YAg4yMdcVmbFtOVxjFO4IUPwM5psbbm4z/hQ6Kc5OOM1IxbchJ8jLfN+VT6kMuCgznkiq9uCWGBnmnXrcZVeR607amDlqUZmG7G38aqktuPHAp07ZOSP1qAnkgda0SMJyHMTu561DJjaT7ZqQ9DzyKrzZ2HJBNWkZNirIdo6UUIG2jjtRVaGdzoAoPbmpEI37WGaYgYZz1zT1GTkdaxZ7cUOVfmK4wOtTrwAetRZOPWrKLlRkYrNs6KcBAu5cMKdhGxnO71oAy4CtmnsCGK8Z9SKzbOhIWJsOUbHtShd0uRzt7GmqrlvmOR61OtojNkFsnrjtUt2NYokh2k4PHvV2IEjGc/TvVI2qiQJkkYzkGpvszRsphlOfQ1mzRI0N3yAAjPpTfMZjxkfQVTS6YON8eWB5qw9yHPEbYH5VNh2sOxk7mJyemTxU3mFVGQOnaoXkSRVVlxn1pCUz8rLj3NIGSGQOw3/e9qWRgAC+N3uarTTIgIJBI6EU2KN53EkhIj6CqI5R7XEWTGMt67e1L54XYgjfGOpqYRxxHMagE9cdabI+PvKOKCGtSB5WBK78MeMVAr43Bvl9wKlaEAFhx7ms66ucSDy3J9fSqSuS3Y07eQMMdQOM1eXCKjqi56HNcub1UGFcl6mXWGVChJPHWq5GZSaOyi4Cl2Kg9xWil3HbxbVkIf8AiLdhXnUmszSYAcgDnAPegTz3IwA5o9m+pnZS6na3viC3hZlWZ5SR/DwKyZvFF5gpAqxg8hj1qhZ6LdXB+ZfLHctW5F4atERWuTJM59DgCi0UWuSO5hXepXV5hZ7uSTPVEqOLRb67YGK3Mcf95+M12dnaQ2wHk28ce3kkDn86sNPF5ZmkLbR/Ce9Rz22NVW6RRzdj4Whi2veTbz3VOP1ran+z6dpsn2WBItykDAyxHqTTluC7CR4wgJ4BHSsfWrhpQQmT5nyKB6d6V29yopzl7wljHNNpkskAHB4yOp7ismC7+xXizJnacq6+o711MUws7O1tIkBZV3SH/aPasDUYkgvG2gCKcZX2NNG8J8zaezMnUY1SZyjZR+Vx6VqeEMSSSW7PsQjJwfmI9qqEb7Xaw+eLK/hVXTbj7NqUbkEDPf0rTdESVro7QWsJykLS/TfThBsGFlmHHY5piyrHLuC/eX8xViOYk7gcr6d6w1MG2CLMvyrKG9Qwpzef5kSn5SP7p4NSxhpG6kDrnFW1iLA4wCRgk80GbnYsWssqIXC47Eqc5qxBLG8TEthhzhjjNZpiniwYSGQfeUnr9KVp9pDSwsBjrnNTYwkr7DtRlRgFDAY7Bq53UbcMGdAMkfxc1tyjeGwVkXGRwM1k3NqrK/l71bqAOlXHQFocjqESfe27T0AFcxqCKWJ2kHOM+td3fWkbwMAh3DrznFclfw7S27kDsa6qcjGtDmRz5GDnvmpkGRgflTbhdsvHTNPjGec49q6HsctNWZYQFVwKkjLAdwPemIRj5uakVsrjsKzN2WYjlRg8A0pc+YQvXpUaZUEjpinrIM7io/DvSEyaGRhOvADA9B3pL6QBCGBAP50lqxNxwAQfSo9XADNt6jrmmtznlu2ZLnn600gA4p5DcH1qJwRkjqK1RztjX7j17VWcE1McEZz0qN+Bwc1SMmSLMAoHHAoqMYwODRVWRNzqArEHdwaWIYfIpN3PPc07DBhjnNc7PfQ8jByvWnhypHFRoGP3qkUHB6moZtFsmRhjIHPXNKr5bkZ9+tRRoyqBnPFWYlCr0NZs3hdkqr8y8HBqz8yIWAODTAGKDgZHrUxJCABuh6VkzoSHx/dDA5PpTSW3AYwaUJ5a7lIye1OiO1ty8A+tSMmiVSAo6nknFXreOMEbhhT6VTEnlDsSelPM21CVB+pqWgZPKqsSAPlNVnsIgGYnP0oRt0Yy2Sc1JlhGPm6mjVE3IEjjjT/V7h15HNWRgDBG1e1KhVtxJw69vWl+zsMSEk5HQ9RQNPuNA4yFwR3NUNTnS2QyHDyHgLT9RvhZwNnrjABrnXuXmILcyE8D0q4RvqTMku7ua4GN+wEdKzpAV+UEnnNa0dgow0wLE9B6VOtimN7Y/nitVJLY55wb3MBLeSQgKPfmrAsi3HmD6VpLGwZvLHHTp2poiAIJyfWq5zHksXdK0WHZ5khZsEDgcZ966W1tI7e3RjGqsT0x0qlpNwSiIMBUOfatEszXHluwIJzmspNsTvsaVtF5kJYDAY4FTiHYSQ+W6AgcH6VUguirgHCp06/yq1HuaQPv25+6F5AqGZ6iNbzYLSMEHcY5qhcoXdQThV5Az1ret7iCZik7Zl6A4rD1Fo1Z4sYOeXPQUWLpSbdjOvZdxeCNuqksfSs+Elp/PdfljAC4HftUr2/my+VCCC2NzZ6ito20UdsqBV29eOpo2O5zUFZGO9w7NkxsMe3Wq0yveW8i55jO5cDkGtaVIpbfAZww/h6EmqkKCF3YkbiQCcdaAUzIgQSyxnjbL8pPvWZfxNb3To+AVPX0roZrfZPJFHgBv3iZqLxFClzBDcoh3MuH44zWkJalTd2mXdCu1vrEK4DNFxz6VqQ2xflCCRzycGuH0K8NhfjOSjcMPau3t5C21sjB6YqZxsznk2izbySQ4Ey557GrwcbQEKkN97B6VRnlJXaUGAPvCq9qXQK7sGAbtxUWMWr6m9DkDG1jxnPrUePMciVePao0yXSTeygDIAPBqQ7mQl85U5yppWMWyBkwGLAFCeAeoqpcKkAzuIPYirskyswDHGR2GfxNZt7NBHE2XB9CTimg1Zl3JUtJ91gTyRXJ65GhJdT3xgVr3t6d2IgAfUmsLUJRKDj73XOOtbwWpUtjnZlBYc4NIq85HapJBzye9OUYHJrpbOWKu7gFGDjvU8SfL/WohuP3akywYZB9qktqxYAAVST0PTHWgqpXPTninBSRluhpJMAY3YAPSpEya0wblCqHjrioNWTEj45HFSwSFZgc7Rjsai1LP2nH3t3Psaa3MJLcy5ScAKOV9KryqWAGasyAgsehP6VWbABrZHLIjYk5A7HmoXP1xUzrwWU8Hk1XY8Yq0ZNk6g7RwaKFB2j6UUEHSjgHPNKHI5ANJgs5AxjuKsRBRwQaweh9DFXEBPXGanDMgG0YJqFz3B4zTonDPz0HrWbNokynOM4BPb1qaIEdcVBu3E9D2BqZGBIHQVmzpgiykoPXg0/zM8cenFQIVL5yQTUwQMBjA9KzZui1HjKk5IHNOeJUYtjKHke1RCbZHjnj0pJZSISDgZ9amwNjgwLLyCPSlZ8qRk8dqriVSAFj3E88UjvIeFAXJ707GbZet8lMHAHY05v3TFmZTkVSVSCvzEk9gatrFuwWUgUmhALgDDRowfpnHWnXN8FHzMwApysEJBGFzXP69f8AmObaI59WHanGN3YHJLUrahei8uRk5jT9at6Pa7nM0+7npWbZW7XEgjjyVHU11NtD5SAJkFe9aS91WQou+rJfsxlO0jg9AKq3MPltgH5RxVlJpYsscD/aJqnNf5JCLz3NZoHFsmg2eS23hiKdEiEbCBuYfdNZpllkbB+UegqaG3JdXJf61RnKKLyx7LgKsgVV5/GtCIjG9pcljnNZXlL97+I+tXbYMyfMMYpMhxRpJhyhz8g7nvV6OeGNA+SxHA9zVW3jRY90hDHHA9Kz7yRmD+UNqZyuPSkSoqWhqSTsGIRTtJOFB/nUVw6OmxgHbps7CqsEsskHzcZ6cc1PFEu0uTmXGOaB3SLumWyR22WZTLIfT7grQmSJFYRxgnor+h71RtsmPZtAZOpqzHMRbFHBIBpMwk22U7qGMtC5BJUnHHQ1TksgdxU4+bIz61sxx+ZEC/DL0B6VAyhlLk4YHgqaWxpGbWhi38Lm3jkVfnjP6Gor5wLKSNhhXTcPY1qsfkLH5YyOSe1crfySzlx5my2XOGbjf9KuKudEHdWZlx2jzxbkKFs+vNb+g3pI+zyttlX7vvVSzsttp50S7puoD54+gqhM7uTMGxcRnkdCa0eugnqdi1ycElgVHXHeo450GfMfA9O1YtjqZlUq2PMxz71KkwZipGCTS5TBqx1UU6CAZcFG7HtSRXX7p/3mEU8nPasO0uVfaucHOKT7Ray3E0MdyjzIPmUHpUOJDiupYu75IyQpdyOhAqhKGfE2/fu/vUM0ZiKsMMT1FUGm+zyFGbdGwyM9jTSHp0Kl/KPPPAIxnA6ise7b94QDkVeu2HmE/wAOMjNZk6733HnjtW0SJFZ/mbcAMY5pDESMtwB0qfyjtweP6VHKCMDOR7VdyOWw1PlcAD6GrKAlyHHGOKiiAY+46VKsj5Ct90d6RLY1shhhifakdgwIPUGpDGWXORu9ajkT5wGxz3pozkPtmAuEDA4JxUepI0c/U47Z/pU9sEFwP7vWoNRJwQVPWmtzCRnSNyST2qB8Nj0qSQ8HHX0qJxlfWtUcsmRTbSPlPtUGRnJ6CnsCTg8+1NcgZHerRjIAzYHJopBnA5NFUSdc3Lhs1KoxgjgVWMZBChieamw2AGauZn0UCaXGQ3QYp4+YAcYqv8xXBbinxRgj7xOahnRF3JTtT3I7Cp1ceXlsD2qqsSA9TkVKipnBXNQ0axZIlyM4BBNTpMTgKnNRRxoGJVRirBA25xn0xWbsaxY9Y5GJO4DNOaFVA3Ek+9RpLvzvOCKlTGMkkk+tQaXCRmVcR/e6CmqhK5c5YnoKGIOWI47U+FTN90dKCLElvGzSKFU8nk1q3GIrdt3XGBVOG4gtFLNhn6BVP9ax9U1oZLMQ0p4CjoKEm2Zy3DVNRNsu1TmRug9KxIYnnmCRgs7n5iaSKO4vLgM2SzHg+ldlpWmw2Nrukw0p5z6VrpBESfMQWFotnF0H1q0WXYHb7vX602aRFG9gQOwPeqShruRmY7YgelZ76stIJpDdynZ90dhVdoiDgDn2rShiCE7R8meBQYWScKPvHnmhMpshtLcAhn7jgVcwM8n5scCk8sAsQcnFOAQgtnDUrk2uVhlpMqCBnjNaAdYoXeZxzwMVAyYXe3GTwD6VQaTzrsLyUUcY6U9yGrj7u6nc43BUPQZ5q3YxuGTzCWB+9z2qpbxrNckyjgHAFaJ3KuyMHLA/gKbB6KxYhkzKVjxt/lVon5VjVTliBmo7SNFUHGWIxj1qxv2XMYCqO+D2qTF7k6sf3uQAoA/GlZQJFGT0yfSqckouZXVGyw4IFaDARxru+6uOT3NIzasOtGEg+QkENjnvRIoOW4wW6DpTCgW5wv3WGRmpwq+cI8qmBxQT5nMeJLwRwiMEAyHntgVjxNNftHPPgxQgImFxV7xnGPMRkOV6E4qPw26zWz2rHB7AVqtI6HTCSSRbtWO8IevUfSs7W7Rt3nxKVf8AiXH6irFwWgRX5Do2ODzitJlLWw805DDIPU0lpqOejucLK5yzxnaw96fFqbkKHJBHcVc1WxDszAqjD8jXP3cM0JwwIFbqzMZytsdVZalHt5Zcg5z3qwiWMTS3NvEBPL9585rglneM9yPepk1Fo157Dih0+xl7SPU7KW5jMf75tpznjvWTdXu/IRQMdM9awRqkgJOcr781ML1JFJU8nihU2iXWi9i7NMzRqxOR3pPtCMvzYxWWbtlLI3TNMRS3z54HWq5DL293ZGnIdqjryeKhMiswz1pFZggAPAp0Malt1I1bfQQbt5I6Cp4ijrnBpjQc/KTmpYwFXH40mQhFJaTGabIBu2cj607YS/y8iklXGCx+b3poiQ+1iHn/ADZK4war6g7owwPmFXLUHcrKee+ai1gBnDY4IyMU09TGS3MSQ5G7GCetQygBR9alkO3I65qFwNoznNbI5JETH5gajm+7SkBj3GKjkyCPSrSMWOX7o69KKQdBxRVGZ1wbBbP3s8UO5fGRjFRBzu+ppwQ7uua5rH0MZXHxYA+Y85qeMjkCoFX5sEVJJIsSEucVDNoablnKggkA+4pkl1FCDvI+lZE2pEtsh4X1NU5HMrYXLvmhU+43XS+HU2ptcRE2wxc+pqoNbuOgxUEGnzT5LDbWhb6OpC5bk+tJqCKjKtLVaEaarKTnZk1ZXVpSMLHyagfT3T7rbecU9LCUMDvAPY5qWoGilU6luW9udmxIsnqeKrHUL0AgjFW47KRwc3De5o/stT96VzU3iX7+5ReS8lTlgE9RRa2jNJ3dj1rWisERCMHA5ya0LWAIvygAE9e9JzS2HyNv3h+mWC2oWQ4JPc1cndRukc4HZR3qOW5jtosN80h6A1Wgie7YSPkIKybvqzRQ6giNdvulOEUVaUKqBFA9OKkZRgKh246gCo1wjdOB0x3pXuNjlDBlC84qVyokZjnJHzVArFXJbhugFWGQiHIGR1J/pQZsRynlovryRUKxZb5MgevvSu26XLcAjFLcSCC03Bup+VaBpWKuoSZ/co+Sep9KjSI24U/wg4J9aI42jIkfDO/Ue1Gq3AZY40wACeKpdg5SWz2FpGY988d6vwkvvKnG8YHqBWIhwo6gDrWppkxKqHIKnIzQzOS6m1aovlGRGG4jv2qK2lMkzvgYztBqk10SNsIwelSWcgDKh+6O3vSM+XQ0LKJVuHZBsXOTj0q3uWW2ILZ+bkeoqkZh9qJOVBYYp0txGHl8pMr0yfWkZtMnEqFwpzgDil3LukI5OMA981TtJhIZG2n05/mKe7DcpUlmA5AoDlKmtQG5tGQjkDOR6isDSD9muRkYPqa6a4RiV8ttxPY9q5a/G27ZePl44rSD6GsVdF3Wixud7kAEcDsaS1uFe3XO4sOMZqO5kWfTwTkle/vVLTifNK5IH6ZprYtq8S3ffPglRj1rOvYlyDz7mtdgUfBIYEcDrVO6Ur0A57mqTOeSMSaBSSrxgj6YqrcabCVJAZSa3InBdw+CxGORwaragy+ShPBHB71omzGSucnPagMQGqoodGOP0rWucfeycn1qKG2LJ5h6VspWWpyyp3ehCw83G4cnrSxO0eQOh65p0kbbzxxUkUBI+YHmi6sZxpvm0LMZLLirCYIBIOPWoEBj2nsDV+NgVAIzn0rFnalpqMXcOg4J60uwEHjPvT0G1QUJxmkwVYgHAPOD2pE2GxhVB68UxwCd4OT6GlLEMOnpmjYysSfmGKZmya0YLMOnpg1Bq2C/y8EflU9mVebkdeDmodQGJXGO/wCNNbmUjFlQhuKqsCjEn8KtTE98VWmOV471ujjkQrjByKryYDHr1qcZ5XoahKnvxWiMJajgTgc0U5UbAooJsdOqsTk44qVTyc8Y71Rkuo4ifmJwarz3bTggHYvbFZcrZ7XtIxReu75EPyHcRWXcXDzn94Tj0pEVn4iUknqTV2zsTvBfkn1osojTnU06EFrZtLgtwK2bW2SEcIM1NCgUYA5XvSxkiQ7vXisZTbO2lTUCVEPQ555PtUisVTB5NI5ZiuOnelY/KMDAB6VidOw5xlOPvUIBxu6daWJxyT096eqh2yenpUspdxbYlWcA4U9DUz7iR/OgKMgAYFKASSSce9Tc0toLmRhgnI9MUjXawjAXc/8AKoZbshDFHjJ/iqSxtQX3S8kc4oGojreEzy75mOfStV2KIFVcLVVSPMIIwKkG53A3YB7VD1GTb0Fvznf1xTQqh95PzdhQzKAS/bv602Iqy7+C56cdKEZvUnjhEwBI+Y8nHanuxJMcRHynBqFWEKsAzbupxVVrhiTHEeCfmfFMXKSTEq5HXIyTSRRNNIWcfu1HFSwx7pWDkMx7mrzJtXauPmovbYpFK4izyP4RkVl3qYukClTnHatkRkgs56cVkXA/0t85POQfSiJUSTyHMbkYJpYJNq4yB9KcrqsOScc/pVeMBpeCQCaozkjUQL5Suv3+p9xQs3lTMgxggMpNVo3dZArDIWn3T72jbaBj3pGVjSWZZNrgdKbI5DKeCpOTiq8Ehhzuxhh0qe22FGIOB6H1pE8tjRzF5ewqFwcgg8/jUXmeS2QwwR2PJqncTr5K4XHOGU9fwqtHKjQshY7k+6KYlEvXsrAEq2AemK5/UmPnI5/HPeteCaN7ck5GOvtWDqzKzxPztAIwKqO5aVizp7g2zqPnDE/hVFJmhnzg8HB4p+iEBJVwS2cjNN1Es7Bl4ZeDjvV9QT6GtHJlQRtJHO6pbmJGQAkFSM5Hasqwu1MDCTh1HGKfHdMS3zHB6HFKxjJakU8S+ft7f3qpamo3479/Q1eWRpHUOOTUeqQfuw2cleDVp6mclocxNGzTbWwVH6VoW8W6P5fu4ziq20iXJwB04q3DJt4TkVpJmcY9SFIsklhxTjHtYcBV96nwHbIG2nNF5pCkEstRcuwxIkIAIH1qaGOMFk7npREhy3JyB0NEkW+DI4IPJFK4NdQmZY4sLywNV2LHknNSogIZe/1qMthSDzg00Ztkax8AdQOahLsVIapTLgHHNQSvu+cDpwatXMZySJ7GXbMMjcOlRan8pcoTnPemRYZspkfSk1kkFTkYI5qktTlczJlYEEnriqTFm4Xg1Zn4U/zqGPIyxFbo5pFZ1dTk9+tNSTLc9qssATyKjkjXsKq5i0TB48DpRUAj4HWiiwrsurG7udozzV2CxLEeaeKtxlFJIFTZ3rwtRKTPXp0YrfUWGBY14/OrMfToM+tV2bGATx9am5KjAzWEjthZbEwLYPrTlXlWOMZ5FRL83fHtU4QA5PQ1mzqirixyANnkCn7nJxtBpSFQ8c/WmtJsGUOSakpkhU7gAPwpybgcDk9qrfaolJYMS1QPesQQgOT3pWbGmkaLSgE+awwPSoJLppSUiBx04qpBC0sgMjHGK07dYoydo/E0mkjSLuLbwCJQWG5z39KuRuFHy9TUSkSMP7tTCNFjDAkqKzbNYosRDoWOSKm8vchkcbFFQRuWwSMf1q5bgON0xynYGoCTIFCMuW6gYUVNHBGCpPygDmnDy2YvjAFJMUEfmE/L1C+tDIWpQvWXf5cR4PJNWra32xBW/i6UyyhDuZnT73QVs2arIpJxx29KG7aDloVooUiQkgFqashkcEDirdygJwOhHFVynlBVJ4GcmlclEDKxXbxg81kH5rxlHPPSt1CEUMwyvasWxZZL2RzgDJNUi11HTRFWCYp6oqYlI/CrMpiPOM4OBTAfTBA68U7kMgwpyxYZp4ZCNuMg+tRj7+Tz3xQCmSMYz60CtcmlbawRuUxgHvTElKMc52npio7gM1s2evUUkP8Aq1HGTz1pi5SSWUyZU5A+lMkUooYNx1B704MQcEZHce1VpgNu1T06ZoDlHJJswWztbrVPV2GBsI2jmp8hxiTJOOKpXxJtGJ6irjuTJWItEnCXbg5wRitS8jCruQHafWub0WUnUAv4CumupcxMrcc8D+tXNWZhF8yujFcNHKCpO3rVxHBQlM4xniieFZEIBwcZWs9C8BbcSPUetG5TVzWEhMGVI+U8etS3BaeAISBx1Pesu0mBBKZ3elSsXdOT8/XFFjNoy7nZEW8wEHNVS7quYzuSta4g85SWXPqO9Zk1hJGGNuxwea0i09zGUWthbe6XIGSD71s24MoVkBz14rkyWT5XyHHNaGlas9u3lyDIPc9qcodURGqtpG1NlZAeffPemsxAODkN0xTzKJADkMp5pmCCQR8lZlyY1WIAYrnP61DnO4FevY9atMwIUqenSoHI37uhNNGbKk67V3L0zzVbcVQ8dauXCAKWyMelUZc7DlgB7elaxOWqiSCQMQeM9Kk1Q5hj3cgjGapIAmc1aZxNY7Bjchz9RVWOa/QxLjke9KV2w5U8E0k+CnvnFLEcxlR/KtTJ7lfvmkYZ5PSpnRgMnGKgk+7149qaM2hw6Dk0UKr7RgjFFMix0DJgluxNTJ0GOR+VOKjcwxxUewrnafwrJu57kVYlIAHNIkhY4zUHmOxAbNSmSOI5OC2Kho1UuxagwZTuHA4OakkuokBA5x0rPaSWYgA8GrMVoOC7c1m13OqEn0GPdyOw2jANOjSaQnsPep2jRT8nbvTsseBnFTfsWk+pWNntzuYk57VPbxhCM43VOwO3IPPrT0CgDJyalyK5ddB8ZUPk89qlflsg49RVdV5OOTVgLxnqe9Zs1iiSI4I7Yqzksh4AWq8fIHpUqvwwxUs1RKjZCk5KirtvKHUdc+9Z0T/NgfdqY7uoGF9qViJalySQZ+X7zHiqckRmuAAxwvJz3p4nEXUZJ4FW7NcKTjLN1pbDXuomtPlZQBkDjgVoTgRgKm3ceoFVYwYUJxgelMaVpJN2TmpFa7uS7iZtgGcDr70yUHI877uecVYwVAUntke5pkhL4Tj5RSH1IbhljsJWU9BxXP2QZo2YDGDjitXWXVLfyhwTwcVW0+LESjkDqapbFpWRMiEx53dR0NIucrux83FLCSw4PGakKgFtx7cH0oIaKcnzSqB1BxSR5LsrdCcdORUjIT868kd6V/kJZTgt1pjRA5CNtJzSbRHjH1ANWjGkuGYEN0zVZ4j5mDkECmmFhqNhsgkZpLhY/MPGPcdDT0+cKNvQ4PtTnjOcE8ZIpiaK0qbCD196r36hrF2UYDCrjRDyydxIHXmq86sbORAcqeVxVRZElc5nRxjUVJ6V1k6qAH25BFcxp6eVfBmBPNdhMqiFQrb1PT2rSo9TmoxsjOaIuA4OO/Pej7Ok8W3bkjv3qWEnJU8egx1pELROGAwP51FzRxMd4pbKcEKcA9cVcW5WZlU4Rh0rYuI1liD7dyEViXtiyHzVUiM84qk77k2RaljdmEkfJx8wxQEhK8qV/wA9Ko2WoNDLtOSM45rWYLKhaLDDHK0PQhoxdR0tbhS8Y6dxXL3Vu9u5Vwc+vtXfWcbCOQE8ehrF8S2XKyHliOD7VrTnZ2Zy1qV1dbmfodzkGOQ5P8Oa25CY12OCAea5W2zDOp3Y5zXXOzSRJIBkBevrTmrMik7qzKso4BTGe4PFQndj5hinzSqvLr0qvJeIflwf8KlJlNoivDg7QeT1FVmC7PmGKfLMhfc59qY8iMmC3FaI5amrKzvnI7ZpYJfKzuOAfWoppl5AFVTvlOMZrVI5Zbk8kZkdthUjrTxCY4qmtAUBBA4FSbw5IxgUmyLdzNl4XqMVXk5BFW7hQHIAyuKqfxVaIkIAcdvzop4Y4opmdjppGOciggkg+lRyusfHBOaiZ2kOE4FZ2PaTFu5hwqgZ9abBBuYM/f1pRFxknJqSOQlQOBSe2hUdXdlldoG3pUiEY2moTwAT1pQSzcfSsmjriywMdB+fpT/vsoJqFcgY6Cn56YGSepqGapk6FUJ5NLH3OOtRIS5C4qfyigwvHPOahmkSRQyDtUyHPfAFRq3PzHgcUhbDk4yKhmsWW0PzZ7U7ZuAwetV1fecLUpYLjaST39qmxTJUYc57Dmla4Gzg/KvP1qGSVVXk/h61CkUk5A+6OtOwki1bZllEkg69FPatm0ZYxuHP+NZUCNHKFduOxFXvNVY1HQZzxUPUp6ovh2dwTjBPejYu47Tnvmq8Dh2UsSFFSq69Dkc9qknYmkZRGPN65xUbyxhvkOCR1ps7RrwOnUk1QvZAkW4dxQkOKuUr+T7Rehe2cZq6YmSNQpHT8qqaagdmkft+tXwVaM5IBpvsaPsNg+Vdo5NKoPIJ47mnLtQHPDAUxnDBgDtz0zSIERlEZC9ehzTlTAKsR04qNSqDYepPWpJCVxlQw6ZoBDLhM4ZDgjqBUDZeXJJ9qtxyxqwJU5PUCopo9zFtwC9qaDYhg/cS7mG6N+v1q2kSssjcMByBVJ2ITYOcdKktJmhyTyCMYqhNCXK7ofMQ9OCKohg0TLj/APXV6RkYMv3CT09apumyQ8YGe1NE9DDdvLuCwHQ8iumt50ltgMbTxg+hrm78N5+5OcnmtnT8Nb/MOa0nqjKMdWWhs3qzEA9CPekkid8jGFPK+9RBiDtC5P8ASrK4UKxfKfyrMclbYbYhlYpJwvpV+e3UwBFOc8kVQutwZWU8deKu2zO9uQpHmDtTMZLqcxfWWZCV4YdsdaitJWifYcgiuhubRjL5jKdh9ayLy2w7Mh+YenpWiZOjNa1EU7bhxkYPNZetqxiaLO4LyDUVrc+S6vg571eu0SeJnQ4LChaMmSOIuUwQ2OQa27KUfYDkkECsy6TDuh4OaltnBtpEB5HOK3lqjjhpIiy08m3eTzzVhrJcdTn1pungmRiBx3qzGxVnGeM9DSb7Bp1KMtpkZ796qzQorr81bTqPLJB+Y1TkVHXkAEetUpGE4ozmt14BYHNOMZA/djFTMqHOBz6VGxyuQ3TiruYNDYZGjkzk5q0THJyB16iqjLxnOTTVm2EAjina5lJiX0YDhgufWqEqkHOCM1rkhhuGGBqncxjB4/CmmRIpgHA5opNntRWhnqbfll3LP0zVhBtUYFOO3kDikZ+MHFZt3PUirCEg8dBUY+VunFOCseTinmPcvPWkzWOo5WBGTUo459KgiVlHIHHpU4OQDzWbOmHmSGTPHIp6M2Dx1qFeeCPan7SMe3Ws2bRZZt0+bc3QVMsm+TrxVdG+XBJ20qEI4PaoaNk7Fwx5YbSQB7UYUgjn3p0NwHUgnkUMxAwQB+FZm8UM3eU+AOopC+w5POe1KQuQeopGYPKNoGB1oB6j4Ytx3yc9wDV+AMThOTVeIYUetX4cRcHGSOoqZMEDsxbbt+Yd6SNy5CyYJHSpC/zDPNMfGVbHfFSWTFyH2LwB3qRZDyP4hVdSxbK5xSyMN4AOMHk0CJW3MDuGB396zr6ct8g4HQCpru4O3Knk9vSqNr+8uPMkHyrzTS6lx7mhbKyxJH0z1NSsM9MDFIDuw2MCpMAl2P3egqWybiZJzuH404PuhwVGc9aYx+ZMDKgUO5MW0AAetAWEQqqktgmlMmIyFzz0NQx53fNjA9utPO1mIBIIFAMdtZSG6/3qdJIpJUjjp1qEuwGCTj3qB3MW0MrMc44/nTSEOxtcHqAeppUfEyjAA601sg4AyD1pSuCMfdHOaYguCGGT9OKoXM4Cbc/MeAfSr94PLjz/AAkZzXOSTsXZvXgVcFciT0HD95cKNxwO+K24HCxHbzxg1nWluAAW5zzWlbxgLjnHpTk7iirEYkZ5OmNtW7SPeSGOAagjUCU5HHWp3DpyGzGenqKgbHjEU5GNwxnk1YjUrMskJycZI9RUDKGXO75scVchlTydoXDetMwmWS4mi2SjAPINZk1sm47hhhnGO9WIbhYhsf5lzxz0p775QGxhv4SPT1oRi1Y5m9iEchbGCabBP5YxjFaeqW21Dk575NUoVUxlmUEr19xWq1QX0MTWrYqRKp3Ke9ZiSmPGATmuovo0kh2pjaRwPSuUuUaORkJ6HNbQd1Y46vuu6NWwUIN6HJPXNWWUmQkCqGkXAKbWwSPWtl+EG0ncRyKT0YlqikMbGGRyeM1WnXjgc1OwCv8APnnoaglzu6800Zy2Kqrgc8UjoCnGD3qwAADmq7kbj/CtUjFoqS/K1Rg5B9allw2do+WoO2DWiOeWjHxP5bErn3FSviePcg7c88iqcjYbK9cURSheoxn0p2M2yRUXaOnSipgIsCigRpyAbjx3oYDevAoopM9BE4A8voKewG08DpRRUM6YkUXQfjU5A3jiiipZtEkUDzOnenY5aiis2dKJQox0FO2jceBRRUssfAo8snAzViIDbLx0oorNmsNiMAYxjjmn2qjceBRRSGi0AN7cDtVmMDanA+9RRUssluPvUkIBByAaKKlB0Hw/c/Cq0naiigEUbno31q3bAeT0HSiiqexRYi6D61MgzBzRRUMBMDzBx6Uij5P+BUUUIOhFJxIMe9Mj/wBefoKKKYEkoGwfWmIP3g+lFFNCBwMjiiEAvyM/LRRQQ9irqv8Ax4f8BNYdsAXXIB4oorWOxMjXQARDHrV2ADf0ooqGMRh8x+tWSAbc5A7UUUhMYgGF4FJH/rX+lFFNGUh7AeWeBWxAB9mHA7UUUMxnsZ96oO8EAjmufAAd8AdKKK0gZspH/WKO2Ky9UVd4OBn6UUVtDcwrbFPTQPPHHeuonUAjAHaiinPcxp/CVrwDA4HWqkgGBwKKKSEyMqMdBUE6rz8o/KiirRlIqADZ0HSqhAwOB1oorRHPMinA39O1RAUUVSMWTqBtHA6UUUUxn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade II showing the halo of disc edema is circumferential.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade 3 showing obscuration of a major vessel as it leaves the optic disc (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade IV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade IV showing obscuration of a major vessel on the optic disc (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n grade V",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade V showing complete obscuration of a major vessel on the optic disc and partial obscuration of all major vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37146=[""].join("\n");
var outline_f36_17_37146=null;
var title_f36_17_37147="Mechanisms HIE";
var content_f36_17_37147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mechanisms HIE",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Anatomical unit",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Maternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Impaired oxygenation",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Inadequate perfusion of maternal placenta",
"       </td>",
"       <td>",
"        Cardiorespiratory arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Placental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Abruptio placenta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tight nuchal cord",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cord prolapsed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        True knot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fetal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Impaired fetal oxygenation/perfusion",
"       </td>",
"       <td>",
"        Fetomaternal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal thrombosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sidhartha Tan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37147=[""].join("\n");
var outline_f36_17_37147=null;
var title_f36_17_37148="Anesthesia choice in pregnant women with cardiac disease";
var content_f36_17_37148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The anesthesiologist's considerations when evaluating the cardiac parturient for cesarean delivery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk consideration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Example",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible preferred anesthetic technique&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High likelihood of requiring DC cardioversion",
"       </td>",
"       <td>",
"        History of arrhythmias",
"       </td>",
"       <td>",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A drop in SVR could be compromising",
"       </td>",
"       <td>",
"        Cyanotic congenital heart disease",
"       </td>",
"       <td>",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negative ionotropic effect of general anesthetics could be compromising",
"       </td>",
"       <td>",
"        Markedly impaired cardiac contractility",
"       </td>",
"       <td>",
"        Neuraxial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of precipitation of acute pulmonary hypertension crisis from tracheal intubation, inadequate neuromuscular blockade, coughing, etc",
"       </td>",
"       <td>",
"        Pulmonary hypertension",
"       </td>",
"       <td>",
"        Neuraxial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of precipitation of acute pulmonary hypertension crisis from a poor regional block",
"       </td>",
"       <td>",
"        Pulmonary hypertension",
"       </td>",
"       <td>",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboembolic risk requiring anticoagulation at time of neuraxial",
"       </td>",
"       <td>",
"        Possibly a mechanical valve",
"       </td>",
"       <td>",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High likelihood of maternal or neonatal death and maternal preference",
"       </td>",
"       <td>",
"        Mother would like to see baby at least once prior to either's demise",
"       </td>",
"       <td>",
"        Neuraxial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High likelihood of maternal or neonatal death and maternal preference",
"       </td>",
"       <td>",
"        Severe cyanotic or pulmonary hypertensive crisis from anxiety possible",
"       </td>",
"       <td>",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High likelihood of postoperative controlled ventilation or further invasive treatment",
"       </td>",
"       <td>",
"        Immediate postpartum cardiac procedure to be performed",
"       </td>",
"       <td>",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High likelihood of prolonged and complicated surgery",
"       </td>",
"       <td>",
"        Associated maternal intra-abdominal or pelvic congenital abnormalities",
"       </td>",
"       <td>",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of associated abnormalities effecting the airway",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Neuraxial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anesthesiologist prefers a particular technique",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &bull; The patient's complete history and physical exam need to be taken into consideration when choosing an anesthetic. This table of risk factors illustrates how a particular risk may influence an anesthesiologist to choose general over neuraxial anesthesia or vice versa.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dob, DP, Yentis, SM. Practical management of the parturient with congenital heart disease. In J Obstet Anesth 2006; 15:137.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37148=[""].join("\n");
var outline_f36_17_37148=null;
var title_f36_17_37149="Modified de Gramont schedule for gastrointestinal cancer";
var content_f36_17_37149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Short-term infusional fluorouracil and leucovorin for gastrointestinal cancer (modified de Gramont schedule)",
"    <sup>",
"     [1,2]",
"    </sup>",
"    *",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length:&nbsp;14 days.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Diute&nbsp;with 250 mL 5 percent&nbsp;dextrose in water (D5W)",
"        <sup>",
"         &loz;",
"        </sup>",
"        and administer over two hours.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV bolus",
"       </td>",
"       <td>",
"        Slow IV push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         <strong>",
"          Fluorouracil (FU)",
"         </strong>",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after&nbsp;FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        &nbsp;LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &lt;5 percent",
"        <sup>",
"         [1,2]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        <p>",
"         &bull;",
"         <strong>",
"          Dose adjustment for baseline liver or renal dysfunction:",
"         </strong>",
"         A lower starting dose of FU may be needed in patients with impaired liver function. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment by one week if the total white blood cell count is &lt;3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , absolute neutrophil count is &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or platelets are less than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate the day 1 FU bolus. With the second occurrence, reduce infusional FU by 20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment for grade 2 or worse diarrhea and restart at a lower dose after complete resolution",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        <span style=\"font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency",
"        </span>",
"        . Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br>",
"      * This is a modification of the original de Gramont regimen of short-term infusional FU plus leucovorin",
"      <sup>",
"       [4]",
"      </sup>",
"      , which eliminates the day 2 bolus doses of FU and leucovorin.",
"      <br>",
"       &Delta; Leucovorin dose is given for d,l-racemic mixture",
"       <sup>",
"        [5]",
"       </sup>",
"       . Use half the dose for LEVOleucovorin (l-leucovorin).",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Cheeseman SL, et al. Br J Cancer 2002; 87:393.",
"       </li>",
"       <li>",
"        Hochster HS, et al. J Clin Oncol 2008; 26:3523.&nbsp;&nbsp;",
"       </li>",
"       <li>",
"        Fluorouracil&nbsp; injection. FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).",
"       </li>",
"       <li>",
"        de Gramont A, et al. J Clin Oncol 1997; 15:808.",
"       </li>",
"       <li>",
"        Leucovorin calcium injection. FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37149=[""].join("\n");
var outline_f36_17_37149=null;
var title_f36_17_37150="Contents: Pediatric toxicology";
var content_f36_17_37150=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric toxicology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric toxicology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/43/25274\">",
"           Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/57/2970\">",
"           Acute iron poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/57/36759\">",
"           Amanita smithiana mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/28/10698\">",
"           Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/60/22474\">",
"           Approach to the child with occult toxic exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/16/24839\">",
"           Approach to the patient with a suspected spider bite: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/33/8730\">",
"           Arsenic exposure and poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/43/24248\">",
"           Bites of recluse spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15337\">",
"           Button and cylindrical battery ingestion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/19/11577\">",
"           Carbamazepine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10345\">",
"           Carbon monoxide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/23/4473\">",
"           Caustic esophageal injury in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41096\">",
"           Ciguatera fish poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/42/22186\">",
"           Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/47/1786\">",
"           Clinical manifestations and evaluation of mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/10/29865\">",
"           Clinical manifestations and evaluation of potentially toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/50/22313\">",
"           Clonidine and related imidazoline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/30/23018\">",
"           Cocaine: Acute intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/18/7466\">",
"           Cyanide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/1/37913\">",
"           Decontamination of poisoned children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/47/1784\">",
"           Designer drugs of abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/60/17353\">",
"           Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2615\">",
"           Dextromethorphan poisoning: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/13/25817\">",
"           Digitalis (cardiac glycoside) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/32/23043\">",
"           Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26695\">",
"           Enhanced elimination of poisons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/5/2137\">",
"           Ethanol intoxication in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/5/23639\">",
"           Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/2/16426\">",
"           Food poisoning in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/5/27736\">",
"           Hydrocarbon poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/61/33753\">",
"           Inhalant abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/1/7191\">",
"           Isoniazid (INH) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/60/20423\">",
"           Isopropyl alcohol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/62/40935\">",
"           Ketamine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/51/13114\">",
"           Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/60/43974\">",
"           Management of ibuprofen poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/39/42615\">",
"           Management of mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/18/40233\">",
"           Management of toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/31/25081\">",
"           Bites of widow spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21560\">",
"           MDMA (ecstasy) intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/29/474\">",
"           Methamphetamine intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/3/4154\">",
"           Methanol and ethylene glycol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/21/22874\">",
"           Opioid intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/40/20103\">",
"           Opioid withdrawal in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/45/11991\">",
"           Paraquat poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/35/570\">",
"           Phencyclidine (PCP) intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41863\">",
"           Phenytoin poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/41/19098\">",
"           Salicylate poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/22/32104\">",
"           Scorpion stings in the United States and Mexico",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43320\">",
"           Second generation (atypical) antipsychotic medication poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/63/16376\">",
"           Serotonin syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/5/40022\">",
"           Strychnine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/16/13578\">",
"           Theophylline poisoning",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-181BD46765-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_17_37150=[""].join("\n");
var outline_f36_17_37150=null;
var title_f36_17_37151="Incidence of CRC with age";
var content_f36_17_37151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Increasing incidence of colorectal cancer with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The age-specific incidence of colorectal cancer was measured between 2002 and 2006 in men and women of all races.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Surveillance, Epidemiology, and End Results (SEER) Program, 2002-2006. Available online at file://seer.cancer.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_17_37151=[""].join("\n");
var outline_f36_17_37151=null;
